СПОСОБ ПРОФИЛАКТИКИ ОТСРОЧЕННОЙ РВОТЫ

Изобретение относится к медицине и предназначено для профилактики отсроченной рвоты. Используют назальный аэрозольный препарат метоклопрамида в суточной дозе 40 - 120 мг/кг сутки, которую делят на 3-4 приема. Метоклопрамид вводят в течение 24-168 ч после завершения химиотерапии. Способ позволяет предупредить рвоту у больных после проведения химиотерапии. 8 з.п. ф-лы, 5 табл.

СИСТЕМА ДОСТАВКИ С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ ДЛЯ НАЗАЛЬНОГО ПРИМЕНЕНИЯ

Изобретение касается вводимого интраназально препарата для контролируемого высвобождения половых гормонов в системное кровообращение, в частности композиции, способствующей всасыванию активного ингредиента. Композиция обеспечивает высокую биодоступность при очень низких дозах и большую продолжительность действия. 12 з.п. ф-лы, 1 ил., 1 табл.

ВСПЕНЕННАЯ ПАСТИЛКА, СОДЕРЖАЩАЯ ПРИВИТОЙ СОПОЛИМЕР ПОЛИВИНИЛОВОГО СПИРТА И ПОЛИЭТИЛЕНГЛИКОЛЯ

Заявленное изобретение относится к химико-фармацевтической и косметической промышленности и касается пластинчатой формы доставки, растворяющейся или распадающейся в водной среде, для высвобождения, по меньшей мере, одного лекарственного или косметического действующего вещества в отверстие или полость в теле, включающей полимерную матрицу в виде затвердевшей пены с пространствами или полостями, а также, по меньшей мере, одно лекарственное или косметическое действующее вещество, отличающейся тем, что полимером матрицы является привитой сополимер поливинилового спирта и полиэтиленгликоля, состоящий на 75% из поливинилового спирта и на 25% из полиэтиленгликоля. Также описаны способы изготовления таких лекарственных форм. 3 н. и 3 з.п. ф-лы, 1 табл.

КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ РИНОСИНУСИТА

Изобретение относится к лекарственным средствам и касается назальной композиции для лечения индуцированного грибками риносинусита у млекопитающего, где указанная композиция включает водную суспензию, содержащую: (а) от 1-700 мкг суспендированного твердого стероидного противовоспалительного агента, при этом стероидный противовоспалительный агент представляет собой флутиказон или его фармацевтически приемлемые соль, сложный эфир, енольный простой эфир, енольный сложный эфир, кислота или основание, где указанный стероидный противовоспалительный агент имеет указанный в формуле изобреетния профиль распределения размеров частиц; (б) противогрибковый агент, где количество противогрибкового агента составляет от 0,5 до 150 мг; при этом указанная композиция пригодна для введения в назально-параназальную слизистую оболочку. Также раскрыты назальная композиция для лечения индуцированного грибками риносинусита, содержащая в качестве стероидного противовоспалительного агента беклометазон, и способ лечения ...

КОМПОЗИЦИЯ ДЛЯ МЕСТНОГО ПРИМЕНЕНИЯ, СОДЕРЖАЩАЯ ГЛИЦЕРИН И ТАНИН

Изобретение относится к фармацевтической промышленности, а именно к составу местного применения для лечения инфекций кожи и слизистой оболочки, включающему глицерин в количестве от 30 до 99,99% об./об. и проантоцианидины растений; к способу времени удержания глицериновой пленки на биологической поверхности путем приготовления состава и нанесения его на биологическую поверхность; к способу лечения инфекций кожи и слизистой оболочки, включающему стадию нанесения состава; к способу получения заявленного состава. Изобретение обеспечивает формирование долговременной высокоосмотической пленки на поврежденных поверхностях, тем самым сохраняя повреждения очищенными от всех свободных загрязнений. 4 н. и 7 з.п. ф-лы, 9 ил., 11 пр.

КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ФИНАФЛОКСАЦИИ, И СПОСОБЫ ЛЕЧЕНИЯ ОФТАЛЬМОЛОГИЧЕСКИХ, УШНЫХ ИЛИ НАЗАЛЬНЫХ ИНФЕКЦИЙ

Группа изобретений относится к медицине, а именно к оториноларингологии, и предназначена для лечения ушных инфекций, обусловленных хинолон-резистентными микробами, в частности Ципрофлоксацин резистентными микробами. Фармацевтическая композиции включает финафлоксацин или его фармацевтически приемлемую соль в концентрации 0,1-1,0 мас./об.%. Также обеспечивается способ лечения острого отита наружного уха или острого среднего отита с тимпаностомическими трубками, обусловленных хинолон-резистентными микробами, в частности Ципрофлоксацин резистентными микробами. Указанный способ включает инстилляцию ушной композиции для местного нанесения, включающей финафлоксацин в концентрации 0,1-1,0 мас./об.%, в наружный ушной канал субъекта. Использование группы изобретений позволяет повысить эффективность местного лечения ушных инфекций. 3 н. и 13 з.п. ф-лы, 8 ил., 3 табл., 12 пр.

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ

Изобретение относится к жидкой фармацевтической композиции, содержащей от 0,05 мг/мл до 0,5 мг/мл карбетоцина или его фармацевтически активной соли. Значение рН композиции составляет от 5,1 до 5,9. Композиция может дополнительно содержать буферный агент, антиоксидант и агент для поддержания изотоничности. Также описана жидкая фармацевтическая композиция, содержащая от 0,01 до 4 мг/мл фармацевтически активного соединения FE 202767 или его фармацевтически приемлемой соли. Значение рН композиции составляет от 5,1 до 5,9. Также описаны наборы, содержащие указанные жидкие фармацевтические композиции. Фармацевтические композиции по изобретению обладают улучшенной стабильностью. 5 н. и 17 з.п. ф-лы, 7 ил., 7 табл., 9 пр.

ВАКЦИННАЯ КОМПОЗИЦИЯ ПРОТИВ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ НА ОСНОВЕ ПЕПТИДА WT1 ДЛЯ МУКОЗАЛЬНОГО ВВЕДЕНИЯ

Изобретение относится к области биотехнологии, в частности к вакцинной композиции против злокачественной опухоли, сверхэкспрессирующей WT1, для мукозального введения для применения в индукции клеточного иммунитета. Вышеуказанная композиция содержит: терапевтически эффективное количество пептида Db126 и терапевтически эффективное количество первого активатора индукции клеточного иммунитета, представляющего собой лиганд TLR7, выбранный из TLR7-II и резиквимода. Изобретение позволяет эффективно индуцировать клеточный иммунитет против раковой опухоли. 5 з.п. ф-лы, 3 табл.

КОМПОЗИЦИИ НА ОСНОВЕ КСИЛИТА, ПРЕПЯТСТВУЮЩИЕ ОТДЕЛЕНИЮ СЛИЗИ, А ТАКЖЕ СМЕЖНЫЕ СПОСОБЫ И КОМПОЗИЦИИ

Изобретение относится к медицине. Описан способ для ослабления аллергического состояния и одновременного уменьшения осушающего действия противоаллергического лекарственного средства. Описан интраназальный раствор для ослабления аллергического состояния, содержащий композицию, препятствующую отделению слизи, в количестве, достаточном для эффективного лечения аллергического состояния, и по меньшей мере одно из ксилита и ксилозы в количестве, достаточном для эффективного уменьшения сухости носовой полости, вызванной композицией, препятствующей отделению слизи. Водный раствор с низкой вязкостью позволяет выполнять быстрое и концентрированное нанесение композиции. 8 з.п. ф-лы, 1 ил.

Пенообразующие композиции и способы доставки активного агента в полость тела

Группа изобретений относится к области фармацевтики, в частности к системам доставки лекарственных средств, и раскрывает пенообразующую композицию и способ лечения инфекции. Пенообразующая композиция характеризуется тем, что содержит пероксид водорода, кристаллы моноглицерида, по меньшей мере одну кислоту и/или буфер, которые присутствуют в количестве, необходимом для обеспечения рН от 3 до 5 в полости тела, выдувающий агент в количестве, достаточном для выдувания пенообразующей композиции и образования пены, и воду. Пенообразующая композиция подходит для нанесения в полость тела при выдувании с образованием пены, пена разрушается при температуре тела с высвобождением в ткани полости тела пероксида водорода при рН от 3 до 5 и представляет собой носитель в виде пенообразующей композиции для доставки активного агента. Пенообразующая композиция представляет собой систему доставки, способна обрабатывать всю поверхность полости тела из-за ее твердой кристаллической структуры и может быть использована ...

ПРИГОДНЫЙ К РАСПЫЛЕНИЮ АДГЕЗИВНЫЙ К КОЖЕ/СЛИЗИСТОЙ ОБОЛОЧКЕ ПРЕПАРАТ ГЕЛЕВОГО ТИПА И СИСТЕМА ДЛЯ ВВЕДЕНИЯ С ИСПОЛЬЗОВАНИЕМ ПРЕПАРАТА

Настоящее изобретение относится к химико-фармацевтической промышленности и касается пригодного к распылению адгезивного к коже/слизистой оболочке препарата гелевого типа, включающего гелевый состав, который содержит активный фармацевтический ингредиент в материале на гелевой основе, включающий адгезивное средство для кожи/слизистой оболочки, причем адгезивное средство для кожи/слизистой оболочки включает карбоксивинильный полимер и, в случае необходимости, геллановую камедь, и его вязкость регулируется приложением внешней сдвиговой нагрузки, и к системе для введения, включающей этот препарат. Препарат обладает высокой адгезионной способностью и высокой стабильностью. 2 н. и 20 з.п. ф-лы, 19 табл., 14 ил.

ПРОТИВОВИРУСНОЕ СРЕДСТВО - КАПЛИ В НОС "ГРИППФЕРОН"

Использование: в фармакологии, конкретно для приготовления интерферонсодержаших композиций, способных сохранить свою биологическую активность, которые могут найти применение как лекарства для интраназального применения, например, для приготовления капель в нос. Сущность изобретения: противовирусное средство содержит интерферон, биологически совместимый полимер и буферную смесь. В качестве интерферона оно содержит генноинженерный интерферон, а также дополнительно содержит антиоксидант при следующем содержании компонентов в 1 мл буферной смеси: генно-инженерный интерферон, ME 1000-500000; биологически совместимый полимер, г 0,005-0,714; антиоксидант, г 0,0001-0,0006. Кроме того, средство содержит альфа-, бета- или гаммаинтерферон. Согласно изобретению, полученное средство имеет вязкость (1,1-30,0)•10-3. В качестве антиоксиданта оно содержит Трилон Б. В качестве биологически совместимого полимера оно содержит поливинилпирролидон и/или полиэтиленоксид. Причем поливинилпирролидон и полиэтиленоксид ...

ФАРМАЦЕВТИЧЕСКАЯ КОМБИНАЦИЯ, ОКАЗЫВАЮЩАЯ ВЛИЯНИЕ НА ФУНКЦИОНИРОВАНИЕ ЦНС, СПОСОБ КОРРЕКЦИИ СОСТОЯНИЙ, СВЯЗАННЫХ С НАРУШЕНИЯМИ ФУНКЦИОНИРОВАНИЯ ЦНС; ФАРМАЦЕВТИЧЕСКИЙ НАБОР; СРЕДСТВО, СПОСОБСТВУЮЩЕЕ ПРОНИКНОВЕНИЮ ЧЕРЕЗ ГЕМАТОЭНЦЕФАЛИЧЕСКИЙ БАРЬЕР ЛЕКАРСТВЕННЫХ СУБСТАНЦИЙ И МЕТАБОЛИТОВ; ФАРМАЦЕВТИЧЕСКОЕ СРЕДСТВО ДЛЯ ЭНДОНАЗАЛЬНОГО ПРИМЕНЕНИЯ

Изобретение относится к области фармакологии и касается фармацевтических средств, оказывающих влияние на центральную нервную систему, а конкретнее фармацевтических комбинаций, используемых при нарушениях функционирования ЦНС. Предложена фармацевтическая комбинация, оказывающая влияние на функционирование ЦНС, содержащая, по крайней мере, одно соединение, обладающее лечебным воздействием на ЦНС, и соединение, способствующее проникновению первого через гематоэнцефалический барьер, при этом в качестве соединения, способствующего проникновению через гематоэнцефалический барьер, она включает средство для эндоназального применения, обладающее рефлекторным, преимущественно нейро- и вазоактивным воздействием на структуры и рецепторы слизистой оболочки полости носа, в основном рецепторы систем вомероназального органа и тройничного нерва, активные формы кислорода,, выбранные из группы: например, супероксид, и/или пероксид водорода, и/или NO-, и/или СО-активные продукты, и фармакологический стабилизатор ...

СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННЫХ И БИОЛОГИЧЕСКИ АКТИВНЫХ СРЕДСТВ

Изобретение относится к фармацевтической промышленности, а именно к способу получения лекарственного или биологически активного средства. Заявленный способ включает растворение бикарбоната натрия и бикарбоната калия в воде таким образом, чтобы соотношение ионов натрия к ионам калия в воде составило 2-6:1. Затем понижают окислительно-восстановительный потенциал полученного раствора до значения от 0 мВ до -900 мВ и растворяют активный ингредиент лекарственного или биологически активного средства в полученном растворе. Технический результат заявленного изобретения заключается в получении лекарственных и биологически активных средств, в которых активный ингредиент присутствует в стабильной во времени восстановленной форме. 1 з.п. ф-лы, 2 табл., 12 пр.

СОДЕРЖАНИЕ ИМИДАЗОТРИАЗИНОНЫ СОСТАВЫ ДЛЯ НАЗАЛЬНОГО ВВЕДЕНИЯ

... 1. Состав, включающий по крайней мере один ингибитор цГМФ-фосфодиэстеразы и по крайней мере один местный анестетик, при том условии, что местный анестетик не является бензиловым спиртом, а ингибитор цГМФ-фосфодиэстеразы представляет собой соединение формулы (I) где R1 означает атом водорода или же линейную или разветвленную алкильную группу с числом атомов углерода до четырех, R2 означает линейную алкильную группу с числом атомов углерода до четырех, R3 и R4, одинаковые или разные, означают линейную или разветвленную алкильную цепь с числом атомов углерода до пяти, причем эта цепь может быть до двух раз одинаково или различно замещена гидроксильной группой или метоксигруппой, или R3 и R4 вместе с атомом азота образуют пиперидинильное, морфолинильное, тиоморфолинильное кольцо или остаток формулы где R7 означает атом водорода, формильную группу, линейную или разветвленную ацильную или алкоксикарбонильную группу с числом атомов углерода в каждом отдельном случае до шести или же линейную или ...

ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, ВКЛЮЧАЮЩИЕ ЭЛЕКТРОХИМИЧЕСКИ АКТИВИРОВАННЫЕ РАСТВОРЫ ГИПОХЛОРИТА

... 1. Фармацевтический препарат, включающий активный агент и носитель, в котором носитель включает водный электрохимически активированный солевой раствор, с содержанием свободного хлора от 1 до 500 мг/л и редокс-потенциалом от +150 до +1350 мВ, и активный агент присутствует в фазе, отделенной от электрохимически активированного солевого раствора. ! 2. Препарат по п.1, в котором содержание свободного хлора составляет от 10 до 400 мг/л, в частности от 100 до 350 мг/л. ! 3. Препарат по п.1, в котором редокс-потенциал составляет от +650 до +950 мВ, в частности от +700 до +900 мВ. ! 4. Препарат по п.1, в котором электрохимически активированный солевой раствор является раствором натрия гипохлорита. ! 5. Препарат по п.1, в котором раствор гипохлорита имеет рН от 2 до 8. ! 6. Препарат по п.1, в котором содержание хлората и/или содержание хлорита составляет менее 10 мг/л. ! 7. Препарат по п.1, в котором активный агент выбран их простагландинов, бета-блокаторов, агентов для снижения повышенного внутриглазного ...

ТРАНСНАЗАЛЬНЫЕ МИКРОЭМУЛЬСИИ, СОДЕРЖАЩИЕ ДИАЗЕПАМ

... 1. Микроэмульсия для трансназального введения диазепама, включающая носитель, содержащий воду, эфир жирной кислоты, гидрофильное поверхностно-активное вещество, полярный растворитель и спирт, при этом жирная кислота и вода содержатся в носителе в примерно равных количествах, а спирт содержится в количестве, превышающем количество каждого из поверхностно-активного вещества и полярного растворителя. 2. Микроэмульсия по п.1, отличающаяся тем, что эфир жирной кислоты выбран из группы, состоящей из этиллаурата, этилмиристата, этилпальмитата, этиллинолеата, пропилизобутилата, изопропиллаурата, изопропилмиристата и их комбинаций. 3. Микроэмульсия по п.1, отличающаяся тем, что гидрофильное поверхностно-активное вещество выбрано из группы, состоящей из Полисорбата 80, Tween. 20, 40, 60 и их комбинаций. 4. Микроэмульсия по п.1, отличающаяся тем, что полярный растворитель выбран из группы, состоящей из пропиленгликоля, полиэтиленгликоля и их комбинаций. 5. Микроэмульсия по п.4, отличающаяся тем, что ...

НАЗАЛЬНЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

... 1. Назальная фармацевтическая композиция, включающая терапевтически эффективное количество лекарственного вещества, при этом лекарственное вещество имеет следующий профиль распределения размеров частиц: (i) приблизительно 10% частиц лекарственного вещества имеют размер частиц приблизительно 0,75 микрона; (ii) приблизительно 25% частиц лекарственного вещества имеют размер частиц меньший, чем 1,5 микрона; (iii) приблизительно 50% частиц лекарственного вещества имеют размер частиц, меньший, чем 2,0 микрона; (iv) приблизительно 75% частиц лекарственного вещества имеют размер частиц, меньший, чем 3,5 микрона; (v) приблизительно 90% частиц лекарственного вещества имеют размер частиц, меньший, чем 5,0 микрон; где лекарственное вещество является приемлемым для введения индивидууму интраназально. 2. Композиция в соответствии с п.1, в которой лекарственное вещество имеет следующий профиль распределения размеров частиц: (i) приблизительно 10% частиц лекарственного вещества имеют размер частиц, меньший ...

КОМПОЗИЦИЯ С ФАКТОРАМИ РОСТА ДЛЯ ПРИМЕНЕНИЯ В ИНТРАНАЗАЛЬНОМ ЛЕЧЕНИИ НЕЙРОДЕГЕНЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ДРУГИХ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ

... 1. Композиция, полученная по меньшей мере из одного содержащего фактор роста компонента крови, для ее применение в качестве терапевтического средства, вводимого интраназальным путем, в лечении нейродегенеративного заболевания или другого заболевания центральной нервной системы, где содержащий фактор роста компонент крови является обогащенной факторами роста плазмой.2. Композиция по п. 1, отличающаяся тем, что композиция является надосадочной жидкостью.3. Композиция по п. 1, отличающаяся тем, что композиция является гелем.4. Способ получения терапевтического средства для применения в лечении нейродегенеративного заболевания или других заболеваний центральной нервной системы интраназальным путем, отличающийся тем, что он включает применение по меньшей мере одной композиции, полученной из по меньшей мере одного содержащего фактор роста компонента крови, где содержащий фактор роста компонент крови является обогащенной факторами роста плазмой.5. Способ по п. 4, отличающийся тем, что композиция ...

СПОСОБЫ ЛЕЧЕНИЯ МЕСТНЫХ МИКРОБНЫХ ИНФЕКЦИЙ

СОЕДИНЕНИЯ ГЕТЕРОАРИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ BTK И ИХ ПРИМЕНЕНИЕ

ИНТРАНАЗАЛЬНОЕ ВВЕДЕНИЕ

АФФИМЕРЫ, СВЯЗЫВАЮЩИЕСЯ С НЕОНАТАЛЬНЫМ FC РЕЦЕПТОРОМ

Изобретение относится к области биотехнологии, а именно к полипептиду для связывания с человеческим FcRn, который связывается с человеческим FcRn с Kd 1×10-6 М или менее при рН 6,0, способу его получения, а также к композиции, его содержащей. Также раскрыты полинуклеотид, кодирующий вышеуказанный полипептид, а также вектор, плазмида, миникольцо, клетка-хозяин, содержащие вышеуказанный полипептид. Изобретение эффективно для увеличения периода полувыведения терапевтической молекулы из сыворотки крови. 11 н. и 9 з.п. ф-лы, 9 ил., 6 табл., 11 пр.

СПОСОБЫ КОНТРОЛЯ И ЛЕЧЕНИЯ ХРОНИЧЕСКОЙ БОЛИ С ПРИМЕНЕНИЕМ HCG

... 1. Лекарственное средство, выбранное по меньшей мере из одного из человеческого хорионического гонадотропина (HCG), в том числе uHCG и/или rHCG, фармацевтически активного аналога HCG и фармацевтически активного метаболита HCG или аналога, для применения в лечении хронической боли, где лекарственное средство вводится нерегулярно в дозировке для подкожного введения человеческого хорионического гонадотропина (HCG) от 120 МЕ/день до 170 МЕ/день или эквивалентной ей.2. Лекарственное средство по п.1, где пациент имеет по меньшей мере одно из фибромиалгии, синдрома раздраженной толстой кишки, хронической артропатии, боли воспалительного характера, постгерпетической невралгии, невралгии тройничного нерва, мигрени, хронической боли в спине и грыжи межпозвонкового диска, невропатической боли, травматического повреждения нерва, болевого синдрома при посттравматическом стрессовом расстройстве, вульводинии и хронического послеоперационного болевого синдрома.3. Лекарственное средство по п.1, где вводимая ...

ОБОГАЩЁННЫЙ ЦИНКОМ И КАЛИЕМ РАСТВОР НА ОСНОВЕ МОРСКОЙ ВОДЫ

КОМПОЗИЦИИ ПОЛИГИДРОКСИЛИРОВАННЫХ БЕНЗОФЕНОНОВ И СПОСОБЫ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ РАССТРОЙСТВ

СПОСОБЫ ПРИМЕНЕНИЯ ИНГИБИТОРОВ КАСПАЗ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ПЕЧЕНИ

КАРБОНОВЫЕ КИСЛОТЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ/ПРЕДУПРЕЖДЕНИЯ ЗАБОЛЕВАНИЯ КОЖИ

ПОВЫШЕНИЕ СВЕТОУСТОЙЧИВОСТИ ОКСИМЕТАЗОЛИНА

... 1. Наружная противоотечная композиция, содержащая: ! оксиметазолин или его фармацевтически приемлемую соль; ! по меньшей мере, одно вещество из двух - поливинилпирролидон или полиэтиленгликоль; и ! буферный раствор, где данная композиция имеет уровень рН от около 3 до около 6. ! 2. Наружная противоотечная композиция по п.1, где композиция имеет рН от около 3,5 до около 5,5. ! 3. Наружная противоотечная композиция по п.1, где композиция имеет рН от около 4 до около 5. ! 4. Наружная противоотечная композиция по п.1, где буферный раствор содержит буферное средство, выбранное из группы, состоящей из лимонной кислоты, цитрата натрия, ацетата натрия, уксусной кислоты, гидрофосфата, дигидрофосфата и их комбинаций. ! 5. Наружная противоотечная композиция по п.4, где буферное средство представляет собой комбинацию лимонной кислоты и фосфата. ! 6. Наружная противоотечная композиция по п.5, где буферный раствор содержит раствор лимонной кислоты и фосфата, содержащий около 0,1 М лимонной кислоты и ...

ХИНОЛИЛ-СОДЕРЖАЩЕЕ СОЕДИНЕНИЕ ГИДРОКСАМОВОЙ КИСЛОТЫ, СПОСОБ ЕГО ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО СОЕДИНЕНИЕ, И ЕГО ПРИМЕНЕНИЕ

... 1. Хинолилсодержащее соединение гидроксамовой кислоты, имеющее молекулярную структуру формулы (I)где каждый из Vи Vнезависимо представляет собой водород, галоген, группу -OCF, -CF, -NO, -CN, -ОН, -NH, -NMe, Салкил, Салкенил, Салкинил, Сциклоалкил, Сгетероалициклил, Салкокси, Сциклоалкилокси или Сгетероалициклилокси;один из R и R′ представляет собой группу Q, содержащую гидроксамовую кислоту, а другой представляет собой водород, метокси, метоксиэтокси или группу Q, содержащую гидроксамовую кислоту,где группа Q, содержащая гидроксамовую кислоту, представлена формулойА представляет собой О, NH, S(=O), Салкил, или А отсутствует, и водород в А может быть замещен G;L представляет собой Салкил, Салкенил, Салкинил, Сциклоалкил, Сарил, Сгетероарил, Сгетероалициклил, или L отсутствует, и водород в L может быть замещен G;J представляет собой О, NH, S(=O), Салкил, Салкенил, Салкинил, Сциклоалкил, Сарил, Сгетероарил, Сгетероалициклил, или J отсутствует, и водород в J может быть замещен G;X представляет ...

ПРОЛЕКАРСТВА ДАНТРОЛЕНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Стабилизированные композиции связанных с белком каннабиоидов

СПОСОБЫ КОНТРОЛЯ И ЛЕЧЕНИЯ ХРОНИЧЕСКОЙ БОЛИ С ПРИМЕНЕНИЕМ HCG

СОСТАВ ПОЛИИНОЗИНОВОЙ-ПОЛИЦИТИДИЛОВОЙ КИСЛОТЫ (ПОЛИ-(I:С)) НА ОСНОВЕ ГОРОХОВОГО КРАХМАЛА ДЛЯ ПРОФИЛАКТИКИ И/ИЛИ ЛЕЧЕНИЯ ИНФЕКЦИЙ ВЕРХНИХ ДЫХАТЕЛЬНЫХ ПУТЕЙ

ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ

... 1. Жидкая композиция, содержащая карбетоцин или его фармацевтически активную соль, где значение pH композиции составляет от 5,0 до 6,0.2. Композиция по п.1, представляющая собой водную композицию.3. Композиция по п.1, где значение pH композиции составляет от 5,1 до 6,0.4. Композиция по п.1, где значение pH композиции составляет от 5,2 до 5,65.5. Композиция по п.1, где значение pH композиции составляет от 5,26 до 5,8.6. Композиция по п.1, содержащая буферный агент.7. Композиция по п.6, где буферный агент представляет собой янтарную кислоту.8. Композиция по п.1, содержащая буфер.9. Композиция по п.8, где буфер представляет собой сукцинатный или цитратно-фосфатный буфер.10. Композиция по п.6, где присутствует только один буфер или буферный агент.11. Композиция по п.1, где концентрация карбетоцина составляет от 0,01 до 55 мг/мл, например от 0,01 до 10 мг/мл, например от 0,01 до 1,5 мг/мл.12. Композиция по п.1, дополнительно содержащая антиоксидант.13. Композиция по п.12, где антиоксидант представляет ...

МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С ТИМУСНЫМ СТРОМАЛЬНЫМ ЛИМФОПОЭТИНОМ (TSLP), И СПОСОБЫ ПРИМЕНЕНИЯ ТАКИХ МОЛЕКУЛ

ЕМКОСТЬ ДЛЯ ТЕКУЧЕЙ СРЕДЫ И СИСТЕМА БЕЗВОЗДУШНОГО ДОЗИРОВАНИЯ ТЕКУЧЕЙ СРЕДЫ С ИСПОЛЬЗОВАНИЕМ УПОМЯНУТОЙ ЕМКОСТИ

... 1. Емкость для текучей среды, содержащая: ! корпус емкости, содержащий верхнее и нижнее отверстия и дополнительно содержащий плечевой элемент и боковую стенку, которая продолжается между верхним и нижним отверстиями; ! ограничитель, примыкающий к плечевому элементу упомянутого корпуса емкости; ! скользящий клапан, совершающий скользящее движение по внутренней поверхности боковой стенки упомянутого корпуса емкости, при герметичном уплотнении между ними, при этом упомянутый скользящий клапан в сочетании с боковой стенкой упомянутого корпуса емкости ограничивает пространство емкости для вмещения текучей среды; и ! нижнюю крышку, перекрывающую нижнее отверстие упомянутого корпуса емкости; ! причем упомянутый ограничитель и упомянутый скользящий клапан содержат поверхность ограничителя и поверхность клапана, соответственно которые расположены взаимно противоположно друг другу и наклонены под углами наклона от 5 до 30° относительно горизонтальной поверхности. !2. Емкость по п.1, в которой поверхность ...

ПРИГОДНЫЙ К РАСПЫЛЕНИЮ АДГЕЗИВНЫЙ К КОЖЕ/СЛИЗИСТОЙ ОБОЛОЧКЕ ПРЕПАРАТ ГЕЛЕВОГО ТИПА И СИСТЕМА ДЛЯ ВВЕДЕНИЯ С ИСПОЛЬЗОВАНИЕМ ПРЕПАРАТА

... 1. Пригодный к распылению адгезивный к коже/слизистой оболочке препарат гелевого типа, включающий гелевый состав, который содержит активный фармацевтический ингредиент в материале на гелевой основе, включающем адгезивное средство для кожи/слизистой оболочки. ! 2. Пригодный к распылению адгезивный к коже/слизистой оболочке препарат гелевого типа по п.1, в котором обрабатываемая слизистая оболочка представляет собой слизистую оболочку носовой полости, глаза, уха, ротовой полости, прямой кишки, влагалища или мочеиспускательного канала; или обрабатываемая кожа представляет собой кожу руки, пальца, ноги, тела, паховой области, кожу головы, области заднепроходного отверстия или области гениталий. ! 3. Пригодный к распылению адгезивный к коже/слизистой оболочке препарат гелевого типа по п.1, в котором обрабатываемая слизистая оболочка представляет собой слизистую оболочку носовой полости. !4. Пригодный к распылению адгезивный к коже/слизистой оболочке препарат гелевого типа по любому из пп.1-3 ...

СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ УЛУЧШЕННОЙ ДОСТАВКИ МАКРОМОЛЕКУЛ

... 1. Композиция для улучшенной доставки антитела через эпителиальные слои, содержащая эффективное количество антитела и вещество, способствующее проникновению, где вещество, способствующее проникновению, представляет собой Pz-пептид. ! 2. Композиция по п.1, в которой антитело представляет собой scFv. ! 3. Композиция по п.1, в которой антитело специфически связывается с антигеном-мишенью, выбранным из группы, состоящей из TNF-альфа, амилоида бета, растворимого рецептора лиганда-производного амилоида бета, моноаминооксидазы-B, L-3,4-дигидроксифенилаланиндекарбоксилазы, ацетил-коА-карбоксилазы, рецептора N-метил-D-аспартата (также известного как GRIN1), GRINA, GRIN2D, GRIN2C, GRIN3B, GRIN2A, GRIN2B, GRIN3A, гистаминового H1-рецептора, мускаринового рецептора (также известного как CHRM1), CHRM2, CHRM3, CHRM4, гипокретинового рецептора 1, гипокретинового рецептора 2, 5-гидрокситриптамина (также известного как HTR1A), допаминового рецептора (также известного как DRD1), DRD2, DRD3, DRD4, DRD5, адренергического ...

СПОСОБЫ И АППАРАТ ДЛЯ ЦСВС

... 1. Способ, использующий устройство для эксгаляции, имеющее корпус и сопло, для внесения лекарственного средства в евстахиеву трубу млекопитающего, которое имеет ноздри, для последующего венозного всасывания в цереброспинальную венозную систему (ЦСВС) млекопитающего, причем устройство для эксгаляции способно прикладывать силу давления и имеет резервуар лекарственного средства, соединенный с этой силой давления, причем сопло устройства для эксгаляции выполнено с возможностью приема и передачи лекарственных средств в отверстие евстахиевой трубы млекопитающего, причем способ предусматривает: размещение сопла устройства для эксгаляции смежно с отверстием евстахиевой трубы, использование силы давления устройства для эксгаляции для переноса лекарственного средства из резервуара и через сопло в отверстие евстахиевой трубы млекопитающего, осуществление маневра Вальсальвы, чтобы на выдохе перемещать лекарственное средство в евстахиеву трубу для последующего венозного всасывания в ЦСВС.2. Способ по ...

СПОСОБЫ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙ

... 1. Фармацевтическая композиция для лечения, уменьшения интенсивности симптомов или предупреждения аллергического заболевания у субъекта, нуждающегося в этом, включающая агонист TLR8-рецептора бензо[b]азепин или его фармацевтически приемлемую соль или гидрат.2. Фармацевтическая композиция по п.1, где указанный агонист TLR8-рецептора бензо[b]азепин представляет собой соединение VTX-378, представленное структурой:3. Фармацевтическая композиция по п.1, где указанный агонист TLR8-рецептора бензо[b]азепин вводят орально, парентерально, интраперитонеально, внутривенно, внутриартериально, трансдермально, сублингвально, внутримышечно, ректально, трансбуккально, интраназально, липосомально, ингаляционно, вагинально, интраокулярно, целенаправленной доставкой через катетер или стент, подкожно, в жировой слой, внутрисуставно, интратекально, или в лекарственной форме с медленным высвобождением.4. Фармацевтическая композиция по п.1, где указанный агонист TLR8-рецептора бензо[b]азепин вводят интраназально ...

НАЗАЛЬНАЯ ВАКЦИННАЯ КОМПОЗИЦИЯ ПРОТИВ ГЕПАТИТА B И СПОСОБ ЕЕ ПОЛУЧЕНИЯ

BIFIDOBACTERIUM LONGUM, СПОСОБНЫЙ БЛАГОПРИЯТНО МОДУЛИРОВАТЬ ИММУННЫЙ ОТВЕТ НА РЕСПИРАТОРНУЮ ВИРУСНУЮ ИНФЕКЦИЮ

ВЕКТОР НА ОСНОВЕ АДЕНОАССОЦИИРОВАННОГО ВИРУСА ДЛЯ ТЕРАПЕВТИЧЕСКОЙ ДОСТАВКИ В ЦЕНТРАЛЬНУЮ НЕРВНУЮ СИСТЕМУ

ТВЕРДАЯ ДИСПЕРСИЯ РИФАКСИМИНА

... 1. Твердая дисперсия рифаксимина, содержащая рифаксимин и фармацевтически приемлемый носитель.2. Твердая дисперсия по п.1, где фармацевтически приемлемый носитель выбирают из мочевины, сахара, органических кислот, полиэтиленгликоля, повидона, коповидона, полиметакрилатов, поливинилацетата, производных целлюлозы, самоэмульгирующихся носителей, полоксамера, глицерилбегената, полиэтиленового производного моноглицерида, витамина E, полиэтиленового или полиоксиэтиленового сложного эфира гидроксилстеариновой кислоты, полиоксилглицеридов, полиэтоксилированного касторового масла или их комбинаций.3. Твердая дисперсия по п.1, увеличивающая растворимость рифаксимина по сравнению с эквивалентным количеством рифаксимина.4. Твердая дисперсия по п.3, где растворимость рифаксимина увеличивается более чем на 30%.5. Твердая дисперсия по п.1, увеличивающая желудочно-кишечную доступность рифаксимина по сравнению с эквивалентным количеством рифаксимина.6. Твердая дисперсия рифаксимина, где растворимость рифаксимина ...

СУХИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ НАНОЧАСТИЦЫ АКТИВНОГО АГЕНТА, СВЯЗАННЫЕ С ЧАСТИЦАМИ НОСИТЕЛЯ

КОМПОЗИЦИЯ ВОДНОЙ СУСПЕНЗИИ, ВКЛЮЧАЮЩАЯ НАНОЧАСТИЦЫ МАКРОЛИДНЫХ АНТИБИОТИКОВ

ВАКЦИННАЯ КОМПОЗИЦИЯ ПРОТИВ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ НА ОСНОВЕ ПЕПТИДА WT1 ДЛЯ МУКОЗАЛЬНОГО ВВЕДЕНИЯ

... 1. Вакцинная композиция против злокачественной опухоли для мукозального введения для применения в индукции клеточного иммунитета, содержащая:(i) пептид WT1 и/или модифицированный пептид WT1; и(ii) первый активатор индукции клеточного иммунитета, выбранный из лиганда TLR, циклического динуклеотида, хелперного пептида, иммуномодулирующего низкомолекулярного лекарственного средства, ингибитора циклооксигеназы, антагониста рецептора простагландина, агониста рецептора простагландина, ингибитора продукции TSLP, ингибитора аденилатциклазы, омега-3-жирной кислоты, агониста PPAR, антагониста дофаминового рецептора, агониста дофаминового рецептора, агониста гистаминового рецептора, антагониста гистаминового рецептора, агониста серотонинового рецептора, антагониста серотонинового рецептора, антагониста рецептора вазопрессина, агониста рецептора вазопрессина, антагониста мускаринового рецептора, агониста мускаринового рецептора, антагониста рецептора адреналина, агониста рецептора адреналина, агониста ...

ИММОРТАЛИЗОВАННАЯ СТВОЛОВАЯ КЛЕТКА И ЛЕКАРСТВЕННАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ, СОДЕРЖАЩИЕ ЕЕ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА

... 1. Иммортализованная стволовая клетка, выделенная из стволовой клетки, выбранной из группы, состоящей из соматической клетки млекопитающего, кроме раннего эмбриона и мезенхимальной стволовой клетки; путем осуществления первичного культивирования указанной стволовой клетки; трансфекции 4 генов, выбранных из группы, состоящей из hTERT, bmi-1, E6, E7, Oct3/4, Sox2, Klf4, c-Myc и p16INK4a, в указанную первичную культивированную стволовую клетку для осуществления генной трансфекции с целью отбора из их числа иммортализованной стволовой клетки с помощью экспрессии STRO 1 в качестве показателя, обладающей способностью репарации теломеров и деления по меньшей мере 200 раз.2. Иммортализованная стволовая клетка по п. 1, где указанная стволовая клетка выбрана из группы, состоящей из естественно отторгнутых молочных зубов, выпавших постоянных зубов, удаленных молочных зубов и удаленных постоянных зубов.3. Иммортализованная стволовая клетка по п. 1, где указанный ранний эмбрион является эмбрионом бластодермы ...

VERWENDUNG VON MOMETASONE-FUROAT ZUR BEHANDLUNG VON LUFTWEG- UND LUNGENERKRANKUNGEN

ARZNEIMITTELZUSAMMENSETZUNG FÜR VERABREICHUNG VON NIKOTIN DURCH DIE NASE

EIN PHARMAZEUTISCHES PRÄPARAT ZUR TOPISCHEN VERABREICHUNG VON ANTIGENEN UND/ODER VAKZINEN AN DIE SCHLEIMHÄUTE VON SÄUGERN

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR INTRANASALEN VERABREICHUNG VON APOMORPHIN

ZUSAMMENSETZUNGEN ZUR NASALEN VERABREICHUNG VON DESMOPRESSIN

Behandlung von Rhinitis, Sinusitis und Rhinosinusitis

Die Erfindung betrifft eine Zusammensetzung, enthaltend als Wirkstoff Ectoin, Hydroxyectoin und/oder Salze, Ester oder Amide dieser Verbindungen zur Anwendung zur Verringerung der Nebenwirkungen eines schleimhautabschwellenden Mittels in einem Verfahren zur Behandlung und/oder Prophylaxe einer Rhinitis, Sinusitis oder Rhinosinusitis.

Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern

WAESSRIGES NATRIUMCROMOGLYCAT ENTHALTENDE MITTEL.

Wässrige Zusammensetzung für präventive medizinische Anwendungen

Wässrige Zusammensetzung zur Anwendung als Nasenspray, Nasentropfen, Nasenspülung, Mundspülung und/oder Rachenspülung, bevorzugt zur Präventionsbehandlung von Nasenschleimhäuten, Mund, Rachen und/oder des Kehlkopfraums beim Menschen zur Vorbeugung gegen infektiöse Krankheiten, dadurch gekennzeichnet, dass sie Wasserstoffperoxid (H2O2) enthält.

Spritzgel-Packung, Verwendung und Darstellung derselben.

Verwendung eines Stifts zur Applikation von Pflege- oder Wirkstoffen in die Nase

Bereitgestellt wird ein Stift zur topischen oder transmucosalen Applikation eines Pflege- oder Wirkstoffs auf bzw. durch die Nasenschleimhaut, wobei die Stiftmasse eine Zusammensetzung aus Trägersubstanzen und mindestens einen Pflege- oder Wirkstoff enthält, der in der Lage ist, auf die Nasenschleimhaut einzuwirken und/oder über diese resorbiert zu werden oder flüchtige Substanzen enthält, die auf die tieferen Atemwege wirken oder über die tieferen Atemwege resorbiert werden. Weiterhin wird die Verwendung eines medizinischen und pflegenden, und kosmetischen Stift sowie einer Stiftmasse und der enthaltenen Nachfüllpatrone zur topischen oder transmucosalen Applikation von therapeutischen oder pflegenden Wirkstoffen beschrieben.

Insulinanaloge

WÄSSERIGE FLÜSSIGE ZUBEREITUNGEN

Ester des Retinols und/oder der Retinsäure enthaltende Aerosol-Inhalate.

Nasencreme gegen Schnarchgeräuche

Verwendung von an sich bekannten, bei Raumtemperatur gelartigen, Gemischen von im wesentlichen gesättigten Kohlenwasserstoffen zur Prophylaxe von Schnarchgeräuche, insbesondere der atopischen Rhinitis vom Typ Schnarchgeräuche Das Kohlenwasserstoffgel wird in Form einer von weiteren Bestandteilen (Vestibulum nasi mit Polysachaccharide 0,5 mg, Natriumchlorid 3,7 mg auf 10 mg), vor allem im Bereich der Nasenklappe (Linien nasi) eingesetzt.

Pharmazeutische Formulierung und Verfahren, die intranasales Morphin umfassen

Spray dispenser for opioid antagonists

Delivery system

NASAL COMPOSITIONS

Drug delivery composition

Nasal sprays/suppositoriers

Pharmaceutical compositions for increasing the resorption of biologically-active peptides e.g. insulin through mucous membranes e.g. nasal sprays or suppositories wherein the pharmaceutical composition additionally contains a protein-fatty acid condensate e.g. a condensate of a glutin hydrolysate with C8-18 fatty acid purified by acidic solvent extraction.

Oxapenems and pharmaceutical compositions thereof

An oxapenem compound which is, or is capable of forming, a zwitter ion of formula Ia or Ib: wherein R is a C1-C8 branched or straight chain alkyl group which includes a protonated basic substituent. The compounds display superior bioavailability and b -lactamase inhibition.

Intranasal analgesic composition comprising buprenorphine, & preferably chitosan or partially esterified pectin

Aqueous formulations suitable for intranasal administration comprise buprenorphine (I) or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50% or (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours. Also claimed are the use of buprenorphine (or a physiologically acceptable salt or ester thereof) and a delivery agent for (i) the manufacture of a medicament for intranasal administration for the treatment of pain and (ii) the manufacture of a nasal delivery device, as well as a composition containing ...

Compositions for intranasal administration

The present invention relates to pharmaceutical compositions for administration to the nasal tract. In particular, the invention relates to dry powder compositions comprising cellulose, and in particular hyroxypropylmethylcellulose (HPMC), and one or more therapeutic agents. It has been shown that administration of HPMC to the nasal cavity is capable of enhancing natural mucus. These powders, and the gel that forms when they are administered to the nasal tract, have now surprisingly been found to be a very effective way of intranasally administering therapeutic agents, and in particular, herbal or homeopathic agents.

Medicaments

Drug delivery composition for the nasal administration of antiviral agents

A drug delivery composition for nasal administration is provided which comprises the antiviral agent ICAM-1 and a bioadhesive material. The bioadhesive material may be a chitosan solution, a liquid formulation comprising a polymeric material or a plurality of bioadhesive microspheres. The polymeric material is preferably gellan gum or alginate. The microspheres may comprise starch, chitosan, hyaluronic acid, or gelatin.

Drug delivery composition for the nasal administration of ICAM-1

Composition

Controllable release nasal system

Novel compounds

INTRANASAL FORMULATION

Nasal delivery

PHARMACOLOGICALLY ACTIVE COMPOUNDS

TRANSDERMAL DELIVERY OF DRUGS

IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS

NASAL SPRAY PRODUCTS

The treatment of inflammatory disorders

Pharmaceutical formulations and methods comprising intranasal morphine

Labelling of dry powder formulations for inhalation

Novel compounds

Drug composition and its use in therapy

Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish

The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.

Stabilized anti-respiratory syncytial virus (rsv) antibody formulations

The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

Nasal spray device

A nasal spray device for the delivery of a pharmaceutical formulation to the nasal cavity in metered doses. The device includes: a pressurised aerosol canister including a vial containing a pharmaceutical formulation including an active ingredient, a propellant and, optionally, a co-solvent, the aerosol canister further including a metering valve having a valve stem; and an actuator for the aerosol canister, the actuator including a stem block having a receptacle into which the valve stem of metering valve of the aerosol canister is received and axially located and being displaceable relative to the vial of the aerosol canister to actuate the metering valve of the aerosol canister, a sump extending below the receptacle, the stem block further defining a discharge orifice for the pharmaceutical formulation and a transfer channel through which a dispensed dose of the pharmaceutical formulation is able to pass from the sump to the discharge orifice.

Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations

Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.

Non-occluding nasal moisturizer and methods of use

Compositions are provided that provide improved nasal moisture, clarity, and lubrication. Compositions are oil-in-glycerin emulsions that include a surfactant promoting emulsification of a hydrophobic or otherwise water insoluble bioactive agent. The compositions are used in methods of promoting improved nasal moisture and reduction in nasal congestion.

Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same

Use of high doses above 1 gm per day of ascorbic acid or the derivatives thereof for the treatment of neurodegenerative and neuro-muscular degenerative diseases and disorders, in particular amytrophic lateral sclerosis, multiple sclerosis, alzheimer's disease, parkinson's disease, and muscular dystrophy is disclosed. Preferably the dose includes mannitol which facilitates the delivery of ascorbic acid to the target cells in the brain. Still further the said dose includes zinc citrate for preventing formation of kidney stones. Dose compositions for various routes of application such as oral, intravenous, intramuscular, nasal and in the form of transdermal patches are discussed.

Cyanocobalamin low viscosity aqueous formulations for intranasal delivery

A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering, intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

Coconut oil-based intranasal composition and use

The present invention relates to the use of coconut oil as an active agent in natural, health-promoting products, particularly for intranasal use.

Bepotastine compositions

Novel compositions including bepotastine besilate are provided such as sorbitol-free compositions, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV.

Compositions and Methods for Treatment of Eye Disorders

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Lipid depot formulations

The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties

It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addtion it is provided a method for preparing the pharmaceutical composition.

Bepotastine compositions

Novel compositions including bepotastine besilate and a corticosteroid are provided, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV.

Device for intranasal administration

Disclosed herein are devices and processes for preparing a vial for an intranasal administration of a medicament where the vial comprises reduced oxygen content.

Stabilizing Alkylglycoside Compositions and Methods Thereof

The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.

Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder

The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.

Palm kernel oil-based intranasal composition and use

The present invention relates to the use of palm kernel oil as an active agent in natural, health-promoting products, particularly for intranasal use.

Preparation for Transnasal Application

Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance. 1. A method for manufacturing a set of capsules containing a powdery formulation for nasal administration comprising:(a) homogeneously mixing a powdery drug with a powdery carrier comprising a first crystalline cellulose; and(b) filling a set of capsules with the powdery formulation, wherein the standard deviation in fill uniformity is less than 3.5%.2. The method of claim 1 , wherein the first crystalline cellulose has an average particle diameter of 30 μm or less.3. The method of claim 1 , wherein the carrier further comprises a second crystalline cellulose or a starch.4. The method of claim 3 , wherein the second crystalline cellulose or starch has an average particle diameter of 30 to 100 μm.5. The method of claim 1 , wherein the carrier further comprises tribasic calcium phosphate.6. The method of claim 5 , wherein the tribasic calcium phosphate has an average particle diameter of 100 μm or less.7. The method of claim 1 , wherein the first crystalline cellulose is present from 60 to 94.9 (W/W) % of the carrier composition.8. The method of claim 3 , wherein the second crystalline cellulose or starch is present from 5.0 to 30 (W/W) % of the carrier composition.9. The method of claim 5 , wherein the tribasic calcium phosphate is present from 0.5 to 5 (W/W) % of the carrier composition.10. The method of claim 1 , wherein the powdery drug is present at a weight ratio of 0.0001 to 1.2 in its free form without being converted to the ...

THERAPEUTIC AGENT FOR INTRANASAL ADMINISTRATION AND METHOD OF MAKING AND USING SAME

The present invention provides a composition suitable for intranasal administration comprising capsaicin, dihydrocapsaicin, and nordihydrocapsaicin in the form of used as a therapeutic agent. 1. A composition comprising:{'i': 'capsicum;', 'an aqueous homeopathic dilution of'}wherein the composition is suitable for intranasal administration to a human in need thereof;wherein fast relief is defined as first relief from at least one rhinitis symptom occurring within about 30 minutes of administration.2capsicum. The composition of claim 1 , wherein the homeopathic dilution of is at a concentration of about 0.00060% to about 0.010% w/w containing about 0.1 to about 2.0 ppm total capsaicinoids.3capsicum. The composition of claim 1 , wherein the homeopathic dilution of is at a concentration of about 0.0020% to about 0.0080% w/w containing about 0.3 to about 1.5 ppm total capsaicinoids.4capsicum. The composition of claim 1 , wherein the homeopathic dilution of is at a concentration of about 0.0030% to about 0.0080% w/w containing about 0.5 to about 1.5 ppm total capsaicinoids.5. The composition of claim 1 , comprising rosemary extract at a concentration of about 0.02% to about 0.25% w/w.6. The composition of claim 1 , comprising rosemary extract at a concentration of about 0.05% to about 0.08% w/w.7. The composition of claim 1 , comprising rosemary extract at a concentration of about 0.06% to about 0.07% w/w.8. The composition of claim 1 , wherein the first relief from symptoms occurs within about 15 minutes of administration.9. The composition of claim 1 , wherein the first relief from symptoms occurs within about 5 minutes of administration.10. The composition of claim 1 , wherein the first relief from symptoms occurs within about 3 minutes of administration.11. The composition of claim 1 , wherein the first relief from symptoms occurs within about 1 minute of administration.12. The composition of claim 1 , wherein the at least one rhinitis symptom relieved comprise nasal ...

Therapeutic agent for intranasal administration and method of making and using same

The present invention provides a composition suitable for intranasal administration comprising capsaicin, dihydrocapsaicin, and nordihydrocapsaicin in the form of capsicum used as a therapeutic agent.

Circumferential Aerosol Device for Delivering Drugs to Olfactory Epithelium and Brain

Methods of delivering a pharmaceutical compounds directly to the olfactory epithelium of a mammal by providing a pharmaceutical aerosol suspension comprising an aerosol and the pharmaceutical compound; aerosolizing the suspension to generate a stream of droplets, the stream having a rotational component, and, delivering the droplets directly to the olfactory epithelium, wherein at least 15% of the droplets are delivered directly to the olfactory deposition. The pharmaceutical compound may be encapsulated within a liposome nanoparticle.

Pharmaceutical composition comprising a curcumin derivative

The present invention is directed to a pharmaceutical composition comprising:

Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract

The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Nasal Wash Solution

A composition provides an isotonic nasal irrigation solution with pH less than about 7.0. The composition may be formed of a salt and a pH buffer and may include an additive. The composition may be mixed with water to form the solution. The composition may aid in the treatment of various nasal or sinus disorders such as, for example, dryness, rhinitis, and sinusitis. The isotonic irrigation solution may also aid in the removal of contaminants from the sinus and nasal cavities such as blood, mucus, dirt, pollen, allergens, viruses, and bacterial. The composition may be liquid or dry. 2. The composition according to claim 1 , wherein the pH of the solution is 6.7.3. The composition according to claim 1 , wherein the pH buffer is selected from sodium ascorbate and sodium bicarbonate.4. The composition according to claim 1 , further comprising one or more additives selected from the group consisting of moisturizers claim 1 , flavorants claim 1 , oils claim 1 , herbs claim 1 , and medicaments.5. The composition according to claim 4 , wherein the additive is selected from the group consisting of eucalyptus oil claim 4 , menthol claim 4 , and aloe.6. The composition according to claim 1 , comprisingsodium chloride between 80% to 88% by weight of the composition;sodium ascorbate between 9% to 20% by weight of the composition; andsodium bicarbonate between 0% to 2% by weight of the composition.7. The composition according to claim 1 , wherein the prescribed amount of water is approximately 100-times the weight of the composition.8. The composition according to claim 1 , wherein the composition is dry.9. The composition according to claim 1 , wherein the composition is packaged in pre-measured amounts or provided in bulk form.10. The composition according to for use in a nasal spray.11. A method of preparing a nasal wash solution comprising: a pre-determined amount of a salt, and', 'a pre-determined amount of a pH buffer, and', 'a pre-determined volume of water,, 'combining'} ...

Methods for Detecting and Treating Rhinovirus Infection

The invention provides a method for evaluating the activity of an agent for treating rhinovirus infection or a symptom thereof, a method of detecting or monitoring rhinovirus infection, and a method of treating rhinovirus infection or a symptom thereof. Various embodiments comprise measuring expression of (i) one or more genes selected from the group consisting of CRY2, B3GAT3, C10ORF95, and BATF3, and (ii) one or more genes selected from the group consisting of RNFT2, BTG4, PSD3, CAPN9, SULT1E1, HEY1, LRRC36, RAB3B, ALDH3B1, FAM134B, FAS, PLSCR1, CLEC2B, HAS2, MX1, SP110, GBP1, IFIT3, IFIT1, CXCL9, CXCL10, and CXCL11, from at least one biological sample to produce a gene expression profile, and comparing the gene expression profile to a reference gene expression profile. Systems, computer readable media, compositions, and methods for maintaining or improving respiratory health also are provided.

NASAL FORMULATION

This invention relates to a solution formulation for nasal administration comprising azelastine, beclomethasone dipropionate, a co-solvent, an acid and an HFA propellant. 1. A solution formulation for nasal administration comprising azelastine , beclomethasone dipropionate , a co-solvent , an acid and an HFA propellant.2. A formulation as claimed in claim 1 , wherein the acid is hydrochloric acid.3. A formulation as claimed in claim 2 , wherein the molar ratio of azelastine free base to hydrochloric acid is 6:1 to 15:1.4. A formulation as claimed in claim 3 , wherein the molar ratio of azelastine free base to hydrochloric acid is 9:1 to 12:1.5. A formulation as claimed in claim 1 , wherein the azelastine is present in the form of both azelastine free base and an azelastine salt.6. A formulation as claimed in claim 1 , wherein the co-solvent is ethanol.7. A formulation as claimed in claim 1 , wherein the HFA propellant is selected from the group consisting of 1 claim 1 ,1 claim 1 ,1 claim 1 ,2-tetrafluoroethane (P134a) claim 1 , 1 claim 1 ,1 claim 1 ,1 claim 1 ,2 claim 1 ,3 claim 1 ,3 claim 1 ,3-heptafluoropropane (P227) and a mixture thereof.8. A formulation for nasal administration comprising azelastine claim 1 , beclomethasone dipropionate claim 1 , ethanol claim 1 , hydrochloric acid and a propellant selected from the group consisting of 1 claim 1 ,1 claim 1 ,1 claim 1 ,2-tetrafluoroethane (P134a) claim 1 , 1 claim 1 ,1 claim 1 ,1 claim 1 ,2 claim 1 ,3 claim 1 ,3 claim 1 ,3-heptafluoropropane (P227) and a mixture thereof claim 1 , wherein the molar ratio of azelastine free base to hydrochloric acid is 9:1 to 10:9.9. A formulation as claimed in claim 1 , wherein the formulation is used for the prophylaxis and/or treatment of seasonal allergic rhinitis (including hay fever) and perennial rhinitis.10. A nasal spray device for the delivery of a pharmaceutical solution to the nasal cavity in metered doses claim 1 , wherein the pharmaceutical solution is the ...

Honey based compositions of a consistency that can be delivered to the respiratory system

A method of treating a respiratory disease in an animal, characterised by the step of administering a composition of a consistency that can be delivered to the respiratory system of the animal, wherein the composition contains a bio-active fraction of honey.

Acute Treatment of Social Phobia

Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3β]-androsta-4,16-dien-3-ol. In some embodiments of the methods, both [3β}-androsta-4,16-dien-3-ol and [3α]-androsta-4,16-dien-3-ol are administered to a patient, and are included in a pharmaceutical composition for the treatment of social phobia.

INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF

The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, and uses thereof. 1. A method of treating or preventing pain without significant sedation in a mammal comprising intranasally administering an intranasally effective amount of dexmedetomidine , or a pharmaceutically acceptable salt thereof , to the mammal whereby the intranasally effective amount of dexmedetomidine , or pharmaceutically acceptable salt thereof , produces a Cof about 0.1 ng/ml within about 15 minutes to about 20 minutes of administration and has an analgesic effect without significant sedation.2. A method of treating or preventing pain without significant sedation in an adult human comprising intranasally administering an intranasally effective amount of dexmedetomidine , or a pharmaceutically acceptable salt thereof , to the adult human whereby the intranasally effective amount of dexmedetomidine , or pharmaceutically acceptable salt thereof , does not produce significant sedation in the adult within a period of time of about two hours after administration and has an analgesic effect within the period of time.3. The method of claim 1 , wherein the dexmedetomidine claim 1 , or a pharmaceutically acceptable salt thereof is administered to a single nostril of the human.4. The method of comprises intranasally spraying in the mammal the dexmedetomidine claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein the spray comprises droplets which have a Dv90 of less than about 150 μm.5. The method of wherein the plasma Cof dexmedetomidine is about 0.08 ng/ml to about 0.2 ng/ml.6. The method of wherein the plasma Cof dexmedetomidine is about 0.15 ng/ml.7. The method of wherein the plasma Cof dexmedetomidine is about 0.2 ng/ml.8. The method of wherein the Tof dexmedetomidine is less than about 1 hour.9. The method of wherein the Tis less than about 50 minutes.10. The method of wherein the dexmedetomidine claim 1 , ...

Nasal delivary device

It is one object of the present invention to provide an air-intake actuated device adapted for delivering a substance to a nasal cavity of a subject, comprising: a. a container for containing said substance; b. a nosepiece extending from said device for placement in proximity to a nose of said subject. c. a valve mechanically connectable to said container, characterized by an ACTIVE CONFIGURATION and an INACTIVE CONFIGURATION; and, d. a trigger mechanism adapted to reconfigure said valve from said ACTIVE CONFIGURATION to said INACTIVE CONFIGURATION, and vice versa; wherein said trigger mechanism is activated by means of said subject intaking air through said mouthpiece; further wherein said trigger mechanism is adapted to reconfigure said valve from said INACTIVE CONFIGURATION to said ACTIVE CONFIGURATION for a predetermined period of time in response to said subject intake of air.

H3 equine influenza a virus

The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.

Parenteral Formulations Of Dopamine Agonists

This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.

Kit providing multiple unmet therapeutic effects

The present invention discloses a unique kit for providing a combinational therapeutic product comprising a medical device and a pharmaceutical composition to treat mammal diseases. The medical device is to meet these unmet needs of cleansing out these harmful substances, such as viruses, multiple drug resistant bacteria, fungi, pollen, dusts, or excessive mucus. The pharmaceutical composition adds the required functions of anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, to have the added effect of the medical device. The method of using the combinational product is also disclosed. The new product can be used to prevent and treat a variety of diseases, such as common cold, drug resistant influenza, sinusitis, post nasal drip, virus-triggered asthma, or chronic obstructive pulmonary disease. In addition, the new kit and the process of use are safe and cost effective.

Use of hypertonic saline to draw fluid out of swollen tissue and relieve nasal congestion

The optimum concentration of salt in solutions to combat congestion of the mucosa is a relatively narrow range. This use of in hypertonic saline solutions for treatment of congestion of the mucosa having a concentration within the range of 2.3% to 2.7% w/v sodium chloride/water with the most preferred concentration being 2.4% to 2.6% w/v of sodium chloride in water brings maximum relief of congestion without causing irritation or discomfort.

System and method for improving outcome of cerebral ischemia

A method for improving outcome following cerebral ischemia is provided. The method includes delivering nitric oxide into the nasal cavity for absorption into the brain through the nasal vasculature and preventing the inhalation of nitric oxide into the lungs to prevent pulmonary vasodilatation.

System and method for improving outcome of cerebral ischemia

A method for improving outcome following cerebral ischemia is provided. The method includes delivering nitric oxide into the nasal cavity for absorption into the brain through the nasal vasculature and maintaining the nitric oxide in the nasal cavity.

System and method for improving outcome of cerebral ischemia

A system for improving outcome following cerebral ischemia is provided. The system includes a source of nitric oxide and an elongate tubular member for insertion into a nose including at least one orifice thereon. The tubular member is coupled to the source of nitric oxide and the elongate tubular member configured for delivering the nitric oxide into a nasal cavity through the at least one orifice for absorption into a cerebral vasculature through a nasal vasculature. A means for controlling flow of the gas, a concentration of the nitric oxide in the gas, or both, is also provided.

APPARATUS AND METHOD FOR TREATING CEREBRAL ISCHEMIA USING NON-INHALED CARBON DIOXIDE

A non-invasive method of treating cerebral ischemia, involving the use of non-inhaled, intra-nasally delivered carbon dioxide (CO2), alone or in combination with other gases to augment cerebral perfusion and improve outcome following a stroke is provided. A vasodilator gas is delivered intranasally, alone or in combination with a second gas, for prolonged periods of time without systemic absorption. The second gas may be selected from NO, hydrogen, xenon, anesthetic gases, oxygen, nitrogen, nitrous oxide, carbon monoxide, or air. The treatment selectively increases cerebral perfusion and provides neuroprotection in the treatment of cerebral ischemia. 1. A method for improving outcome following cerebral ischemia in a patient comprising:inserting an elongate tubular member into the nasal cavity, the elongate tubular member having a proximal end, and a distal end, a lumen extending there between, the lumen communicating with a port on a distal region of the elongate tubular member;plugging the nares of the patient to block inhalation through the nose; anddelivering a gas into the nasal cavity for direct absorption into the brain through the nasal vasculature while preventing the inhalation of said gas so as to not significantly alter the systemic arterial levels of the gas, its metabolites or pH.2. The method of claim 1 , wherein the gas is CO2.3. The method of claim 1 , wherein a flow rate of gas is between 1-200 mL/min.4. The method of claim 1 , wherein a time of use is between 1 minute and 96 hours.5. The method of claim 1 , wherein delivering a gas into the nasal cavity includes occluding the nasal cavity to prevent inhalation through the nose.6. The method of claim 1 , wherein delivering a gas into the nasal cavity includes delivering the gas through an elongate tubular member.7. The method of claim 1 , wherein delivering a gas into the nasal cavity includes delivering the gas via a facemask.8. The method of claim 1 , wherein plugging the nares of the patient ...

XYLITOL-BASED ANTI-MUCOSAL COMPOSITIONS AND RELATED METHODS AND COMPOSITIONS

Compositions and methods for alleviating an allergy condition while also reducing a drying effect of an allergy medication or another anti-mucosal composition. In some embodiments, a nasal solution for alleviating an allergy condition may comprise an anti-mucosal composition in an amount effective for treating an allergy condition and at least one of xylitol and xylose in an amount effective for reducing nasal dryness caused by the anti-mucosal composition. 1. A nasal solution for alleviating an allergy condition , the nasal solution comprising:an anti-mucosal composition in an amount effective for treating an allergy condition;at least one of xylitol and xylose in an amount effective for reducing nasal dryness caused by the anti-mucosal composition.2. The nasal solution of claim 1 , wherein the anti-mucosal composition comprises at least one of an antihistamine claim 1 , a nasal steroid claim 1 , cromolyn sodium claim 1 , phenylephrine hydrochloride claim 1 , oxymetazoline hydrochloride claim 1 , azelastine HCL claim 1 , mometasone furoate claim 1 , and a decongestant.3. The nasal solution of claim 1 , wherein the anti-mucosal composition comprises a natural antihistamine.4echinacea. The nasal solution of claim 3 , wherein the natural antihistamine comprises at least one of claim 3 , chamomile claim 3 , and basil.5. The nasal solution of claim 1 , wherein the nasal solution comprises a nasal spray claim 1 , and further comprising a nasal spray bottle configured to deliver the nasal solution.6. The nasal solution of claim 1 , further comprising a nasal dropper configured to deliver the nasal solution in a liquid drop form.7. A composition for alleviating an allergy condition claim 1 , the composition comprising:an anti-mucosal composition in an amount capable of reducing the symptoms of an allergy condition, wherein the anti-mucosal composition comprises a drying agent effective for resulting in a drying effect on at least one of a typical user's nose, eyes, mouth, ...

Compositions and methods for treating ophthalmic, otic, or nasal infections

The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH THERAPEUTIC AGENT(S) IN PATIENTS WITH CONCURRENT NON-CNS CONDITION(S) OR DISORDERS CONTRAINDICATING SYSTEMIC ADMINISTRATION OF THE THERAPEUTIC AGENT(S)

Methods for delivering therapeutic agent(s) to the central nervous system to treat a first CNS-related disease and/or condition while avoiding systemic exposure for patients having a second concurrent non-CNS-related disease and/or condition wherein the presence of the second disease and/or condition contraindicates systemic administration of the therapeutic agent(s) and/or pharmaceutical compound to treat the first disease or condition. The present invention provides these advantages by applying the therapeutic agent(s) and/or pharmaceutical composition(s) to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and administering the therapeutic agent(s) and/or pharmaceutical compound(s) directly to the CNS. This administration method thus protects the mammalian patient, specifically the second non-CNS-related disease and/or condition, by minimizing systemic exposure to the therapeutic agent(s) and/or pharmaceutical compound(s) administered to treat the first disease and/or condition of the CNS. 1. A method for treating a first disease or condition of a mammal's damaged or degenerating or injured central nervous system , wherein the mammal has a second systemic , non-central nervous system disease or condition that contraindicates systemic administration for treatment of the first disease or condition , comprising:applying at least one therapeutic agent to the upper third of the nasal cavity of the mammal;enabling the at least one therapeutic agent to access the damaged central nervous system by bypassing the blood-brain barrier;treating the first disease or condition of the mammal's central nervous system; andprotecting the mammal's second disease or condition by ensuring that the at least one therapeutic agent is not administered systemically to the mammal.2. The method of claim 1 , further comprising administering the at least one therapeutic agent to a tissue innervated by the olfactory nerve claim 1 , wherein the at least one ...

Compositions for and methods of contrlling olfactory responses to odorants

A composition, system and method for modifying an olfactory response to an odorant is disclosed. In some embodiments, the composition includes crystalline metal nanoparticles dispersed in an aqueous medium. The composition is applied to olfactory tissues using a suitable applicator or dispenser. The metal nanoparticles are believed to interact with a G-protein coupled to receptor located in the cilia to moderate (enhance or reduce) sensitivity or ability to smell particular odorants. In accordance with an embodiment of the invention, the composition includes one or more odorants.

NASAL DELIVERY

A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders. 122-. (canceled)23. A method of treating a condition or disorder , preferably a neurological condition or disorder , comprising the step of delivering a substance , preferably comprising oxytocin , non-peptide agonists thereof and antagonists thereof , preferably as one of a liquid , as a suspension or solution , or a powder , to the nasal airway of a subject , preferably the posterior region of the nasal airway , and preferably the upper posterior , olfactory region of the nasal airway which includes the olfactory bulb and the trigeminal nerve.24. The method of claim 23 , wherein the substance is delivered as a powder claim 23 , preferably containing from about 1 IU to 100 IU claim 23 , more preferably from about 5 IU to about 80 IU claim 23 , still more preferably from about 5 IU to about 50 IU claim 23 , yet more preferably from about 5 IU to about 20 IU claim 23 , still more preferably from about 20 IU to about 100 IU claim 23 , yet more preferably from about 40 IU to about 100 IU claim 23 , and preferably less than about 15 IU or greater than about 50 IU.25. The method of claim 24 , wherein the active ingredient is mixed with a bulking agent claim 24 , such as lactose.26. The method of claim 23 , wherein the substance is delivered as a liquid claim 23 , preferably containing from about 1 IU to about 10 IU claim 23 , more preferably from 3 IU to 10 IU claim 23 , still more preferably from about 3 IU to about 5 IU or greater than 5 IU.27. The method of claim 23 , ...

PHARMACEUTICAL COMPOSITION CONTAINING CYCLOBENZAPRINE SUITABLE TO INTRANASAL ADMINISTRATION

A pharmaceutical composition, containing as active principle cyclobenzaprine hydrochloride, 3-(5H-dibenzo[a,d]cyclo-epten-5-yliden)-N,N-dimethyl-1-propanamine hydrochloride, in form suitable to be administered by itranasal route, is described. Said pharmaceutical composition allows a remarkable absorption rapidity of the active principle, does not undergo the first hepatic passage, has an excellent tolerability with low tonicity formulations and does not show any contraindication in the short period administrations. 1. A pharmaceutical composition comprising:an aqueous solution comprising 5 to 20% w/v of cyclobenzaprine hydrochloride, wherein the aqueous solution has a pH of 6 to 7.4, andoptionally one or more members selected from the group consisting of pharmaceutically acceptable preservatives, buffer solutions, muco-adhesive and absorption enhancer substances,wherein the pharmaceutical composition has a muscle relaxant activity and is suitable for spray intranasal administration.2. The pharmaceutical composition of claim 1 , comprising at least one pharmaceutically acceptable preservative selected from the group consisting of benzyl alcohol claim 1 , an ammonium quaternary salt claim 1 , and a hydroxybenzoic ester claim 1 , in a concentration suitable for spray administration.3. The pharmaceutical composition of claim 2 , wherein the preservative is selected from the group consisting of benzyl alcohol claim 2 , benzalkonium chloride claim 2 , a methyl-parahydroxybenzoate claim 2 , and a propyl-parahydroxybenzoate.4. The pharmaceutical composition of claim 1 , comprising at least one absorption enhancer substance selected from the group consisting of chitosan claim 1 , methylpyrrolidone and sodium cholate.5. The pharmaceutical composition of claim 1 , comprising a phosphate or acetate buffer solution.6. The pharmaceutical composition of claim 1 , comprising a muco-adhesive substance that is sodium hyaluronate.7. A process of administering the pharmaceutical ...

Methods for preventing and treating post-traumatic stress disorder (ptsd)

Methods for preventing and/or treating symptoms of Post-Traumatic Stress Disorder (PTSD) are provided. The preferred method comprises administration of an effective amount of insulin to the upper one-third of a mammal's, preferably a human, nasal cavity, thereby enabling the administered at least one effective amount of insulin to bypass the patient's blood-brain barrier and be directly delivered to the patient's CNS. Another embodiment comprises utilizing vasoconstrictors to enhance targeting of an effective amount of insulin to the CNS while reducing non-target exposure.

Materials and Methods for Treating Conditions Associated with Pathogenic Biofilm

The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.

COMBINATION VACCINE

The disclosure relates to a composition comprising two or more immunogenic staphylococcal polypeptides and a multivalent vaccine composition comprising the immunogenic staphylococcal polypeptides. 1: An immunogenic composition comprising two or more different polypeptides wherein said polypeptides are encoded by different staphylococcal genes selected from the group consisting of:i) a polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO: 21;ii) a polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO: 22;iii) a polypeptide, or immunogenic fragment thereof comprising or consisting of the amino acid sequence as represented in SEQ ID NO: 23:iv) a polypeptide, or immunogenic fragment thereof comprising or consisting of the amino acid sequence as represented in SEQ ID NO: 24;v) a polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO: 20;vi) a modified staphylococcal polypeptide wherein said staphylococcal polypeptide is a polypeptide variant of the amino acid sequences presented in SEQ ID NO: 21, 22, 23, 24 or 20, wherein said sequences are modified by addition, deletion or substitution of one or more amino acid residues which modified polypeptides have retained or enhanced immunogenicity when compared to the polypeptide as represented in SEQ ID NO: 21, 22, 23, 24 or 20.2: The immunogenic composition according to which comprises or consists essentially of 2 claim 1 , 3 claim 1 , 4 or 5 staphylococcal polypeptides.3: The immunogenic composition according to claim 1 , comprising:i) a polypeptide comprising SEQ ID NO: 21, or an antigenic fragment thereof; andii) a polypeptide comprising SEQ ID NO: 22, or an antigenic fragment thereof.4: The immunogenic composition according to claim 1 , comprising:i) a polypeptide comprising SEQ ID NO: 21, or an antigenic ...

Composition with growth factors, to be used in the intranasal treatment of a neurodegenerative disease or other diseases of the central nervous system, and its method of manufacture

The object of the invention is the treatment of neurodegenerative diseases or other applicable diseases by means of the intranasal administration of a composition obtained from at least one growth-factor-containing blood compound, or by means of a therapeutic substance obtained from said composition, in addition to the composition itself. It is guaranteed that the composition reaches the central nervous system in an effective manner in terms of the treatment, and also in a safe manner for the patient.

Methods and Compositions for Enhancing Intranasal Delivery of Therapeutic Agents

A method for treating a patient suffering from a condition with an active compound comprising the steps of (a) treating the patient intranasally with an effective amount of MMP-9 or a functionally equivalent fragment, wherein the tight junctions of the patient's nasal epithelial cells are modulated or wherein the basal lamina of the patient is partially digested and type IV collagen of the patient is degraded or wherein access to the patient's perineural, perivascular, or lymphatic compartment spaces is facilitated and (b) treating the patient intranasally with an active compound is disclosed. 1. A method for treating a patient suffering from a condition in need of treatment with an active compound comprising the steps of:(a) treating the patient intranasally with an effective amount of MMP-9 or a functionally equivalent fragment, and(b) treating the patient intranasally with an active compound.2. The method according to claim 1 , wherein after the step (a) the tight junctions of the patient's nasal epithelial cells are modulated or wherein the basal lamina of the patient is partially digested and type IV collagen of the patient is degraded or wherein access to the patient's perineural claim 1 , perivascular claim 1 , or lymphatic compartment spaces is facilitated.3. The method according to claim 1 , wherein treatment step (a) and treatment step (b) are simultaneous.4. The method according to claim 1 , wherein treatment step (b) is subsequent to the treatment step (a).5. The method according to claim 1 , wherein the treatment step (b) is within 5 minutes to 1 hour after the treatment step (a).6. The method according to claim 1 , wherein the treatment step (b) is within 4 hours after the treatment step (a).7. The method according to claim 1 , wherein the treatment step (a) comprises a preparation of MMP-9 or a functionally equivalent fragment solution having a concentration of 1 nanomolar to 4000 nanomolar.8. The method according to claim 1 , wherein the treatment ...

Method, Apparatus And Kit For The Treatment Of Neurodegenerative Diseases And Impairments

A method, apparatus and kit have been discovered which regenerate with the use of odorants the connections of the neurons of the brain and central nervous system in the treatment of such person afflicted neuro-disorders caused by disease or trauma. 1. A method for the treatment of neurodegenerative diseases or trauma , the method comprising:intranasal administering a blend of odorants dispersed in a media, the odorant blend including at least two of the odorants citrus (orange), lemon, rosemary, cinnamon, banana oil, cumin, vanillin, ethylvanillin, garlic, paprika, curry, nutmeg, thyme, tarragon, celery, ginger, lavender, marjoram, basil leaves, cardamom, cloves, chocolate and anise, the administering including pumping the blend as a part of a flow of gas which includes oxygen and odorant blend, the flow created by a pump which creates a positive pressure to create a flow of oxygen and odorant blend through the nose, the concentration of the blend, the ratio of odorants, the rate of flow of the blend and oxygen, a time of treatment, and the ratios of odorants in the blend effective for effecting an improvement of a neurofunction of a person afflicted with the neurodegenerative disease or trauma.2. The method of wherein the blend includes at least three of the odorants.3. The method of wherein the blend includes citrus claim 1 , lemon claim 1 , rosemary and cinnamon.4. The method of wherein the odorants are dispersed into pharmaceutically acceptable oil which solvates the odorants and the odorants are each in a concentration in the range of from about 0.5 to about 6.0 weight percent.5. The method of wherein flow of gas through the nose is from about 0.5 to about 2 liters per minute.6. The method of wherein the odorants are dispersed into pharmaceutically acceptable oil which solvates the odorants and the odorants are each in a concentration in the range of from about 0.5 to about 6.0 weight percent.7. A method for the treatment of neurodegenerative diseases selected ...

Compositions Containing Moxifloxacin for Treating Otic Infections

Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.

Transnasal Anticonvulsive Pharmaceutical Composition Comprising Poorly Soluble Anticonvulsant

There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant. Also, the transnasal anticonvulsive pharmaceutical composition may be useful to allow the poorly soluble anticonvulsant to show the improved viscosity and/or enhanced solubility in order to effectively deliver the poorly soluble anticonvulsant at a therapeutic dose. 118-. (canceled)19. An anticonvulsive pharmaceutical composition for transnasal administration , comprising:about 1% to about 20% by weight of at least one poorly soluble anticonvulsant,about 40% to about 60% by weight of diethylene glycol monoethyl ether, andat least about 30% by weight of fatty acid ester comprising caprylocaproyl polyoxylglyceride, isopropyl palmitate and sorbitan monolaurate 20.20. The anticonvulsive pharmaceutical composition of claim 19 , wherein the poorly soluble anticonvulsant is diazepam or lorazepam.21. The anticonvulsive pharmaceutical composition of claim 19 , which comprises about 5% to about 20% by weight of diazepam or lorazepam.22. The anticonvulsive pharmaceutical composition of claim 19 , wherein the ...

Stabilized Liquid Anti-RSV Antibody Formulations

The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

Beverage Products

This disclosure provides beverage products comprising a compound of Formula I, such as anatabine, suitable for human consumption.

Antihistamine- and corticosteroid-containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders

There is provided homogeneous pharmaceutical compositions for the treatment of, for example, rhinitis, asthma and/or chronic obstructive pulmonary disease comprising a corticosteroid and an antihistamine, a polar lipid liposome and a pharmaceutical-acceptable aqueous carrier.

NASAL DELIVERY

A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders. 1. A nasal delivery device for delivering a substance , preferably comprising oxytocin , non-peptide agonists thereof and antagonists thereof , preferably as one of a liquid , as a suspension or solution , or a powder , to the nasal airway of a subject , preferably the posterior region of the nasal airway , and preferably the upper posterior , olfactory region of the nasal airway which includes the olfactory bulb and the trigeminal nerve , and preferably in the treatment of neurological conditions and disorders.2. The delivery device of claim 1 , wherein the substance is delivered as a powder claim 1 , preferably containing from about 1 IU to 100 IU claim 1 , more preferably from about 5 IU to about 80 IU claim 1 , still more preferably from about 5 IU to about 50 IU claim 1 , yet more preferably from about 5 IU to about 20 IU claim 1 , still more preferably from about 20 IU to about 100 IU claim 1 , yet more preferably from about 40 IU to about 100 IU claim 1 , and preferably less than about 15 IU or greater than about 50 IU.3. The delivery device of claim 2 , wherein the active ingredient is mixed with a bulking agent claim 2 , such as lactose.4. The delivery device of claim 1 , wherein the substance is delivered as a liquid claim 1 , preferably containing from about 1 IU to about 10 IU claim 1 , more preferably from 3 IU to 10 IU claim 1 , still more preferably from about 3 IU to about 5 IU or greater than 5 IU.5. The delivery device of any of to claim 1 , wherein ...

PHARMACEUTICAL COMPOSITION AND METHODS FOR PEPTIDE TREATMENT

Disclosed are compositions and methods for treating a patient with a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins, wherein the pharmaceutical composition is in the form of an emulsified nasal spray comprising: a macrocyclic permeation enhancer, a liquid carrier comprising water, and a therapeutically effective amount of a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins; wherein the macrocyclic permeation enhancer is a Hsieh enhancer emulsified in the liquid carrier. 2. The pharmaceutical composition of claim 1 , wherein said Hsieh enhancer is selected from the group consisting of 3-methylcyclopentadecanone claim 1 , 9-cycloheptadecen-1-one claim 1 , cyclohexadecanone claim 1 , cyclopentadecanone claim 1 , oxacyclohexadecan-2-one and mixtures thereof.3. The pharmaceutical composition of claim 2 , wherein said Hsieh enhancer is oxacyclohexadecan-2-one.4. The pharmaceutical composition of claim 1 , further comprising a crystallization inhibitor.5. The pharmaceutical composition of claim 1 , further comprising an enzyme inhibitor.6. The pharmaceutical composition of claim 1 , wherein the emulsifying agent consists of a surfactant.7. The pharmaceutical composition of claim 1 , wherein the surfactant is a non-ionic surfactant or combination of non-ionic surfactants.8. The pharmaceutical composition of claim 7 , wherein said non-ionic surfactant or combination of non-ionic surfactants has an HLB of from about 7 to about 14.9. The pharmaceutical composition of claim 1 , wherein the surfactant is selected from the group consisting of an anionic surfactant and a cationic surfactant.11. The method of claim 10 , wherein said Hsieh enhancer is selected from the group consisting of 3-methylcyclopentadecanone claim 10 , 9-cycloheptadecen-1-one claim 10 , cyclohexadecanone claim 10 , cyclopentadecanone claim 10 , ...

Controlled release delivery system for nasal applications and methods of treatment

This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.

METHOD FOR TREATING RHINITIS AND SINUSITIS BY RHAMNOLIPIDS

The present invention is directed to methods for treating rhinitis or sinusitis in a subject. In one embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a formulation comprising an only active ingredient of an effective amount of rhamnolipid. In another embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a corticosteroid, an antihistamine, a leukotriene antagonist, cromylin, an antibiotic, a sphingolipid, or a decongestant. 1. A method for treating rhinitis or sinusitis in a subject , comprising the steps of:identifying a subject suffering from rhinitis or sinusitis, andadministering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a cortico steroid, an antihistamine, a leukotriene antagonist, a sphinogolipid, or a decongestant, whereby the symptoms of rhinitis or sinusitis in the subject are reduced.2. The method according to claim 1 , wherein the first active ingredient and the second active ingredient are separately administered.3. The method according to claim 1 , wherein the first active ingredient and the second active ingredient are combined in one formulation for administering.4. The method according to claim 1 , wherein the second active ingredient is a cortico steroid selected from the group consisting of: budesonide claim 1 , ciclesonide claim 1 , flunisolide claim 1 , fluticasone claim 1 , mometasone claim 1 , triamcinolone claim 1 , dexamethasone claim 1 , and a combination thereof.5. The method according to claim 1 , wherein the second active ingredient is an antihistamine selected from the group consisting of: azelastine claim 1 , olopatadine claim 1 , loratadine claim 1 , ...

SELECTIVE CNS DELIVERY OF MIFEPRISTONE (RU486) TO MODULATE THE TIMING OF THE SPONTANEOUS LH SURGE DURING FOLLICULAR STIMULATION CYCLES

The present invention relates to a new pharmaceutical product containing an antiprogestin molecule, such as mifepristone (RU486), administered by the nasal route and to be used to modulate the timing of the spontaneous LH surge as part of follicular stimulation cycles intended for Assisted Reproductive Technology (ART). In particular, it details the route of administration and the dosages that ensure effective delay of the LH surge without incurring in the antifolliculogenetic effects of the antiprogestinic. It also details the overall treatment method as resulting from the use of the new drug product. 1. A method of temporarily suppressing the spontaneous midcycle gonadotrophin surge in women undergoing follicular stimulation for assisted reproduction (ART) purposes , comprising the step of:administering to the central nervous system (CNS) of a woman in need thereof a pharmaceutical product comprising an antiprogestinic molecule.2. The method of claim 1 , wherein the antiprogestinic molecule is mifepristone (RU486).3. The method according to claim 1 , wherein the pharmaceutical product is administered by a nasal route.4. The method according to claim 1 , wherein the pharmaceutical product is administered starting from the day the leading follicles reach the size of 16 mm in diameter claim 1 , but no later than day 8 of stimulation claim 1 , and is withdrawn as soon as the targeted follicular development has been achieved and a spontaneous gonadotrophin surge is wanted.5. The method according to claim 4 , wherein the pharmaceutical product is administered starting from the day the leading follicles reach the size of 18 mm in diameter.6. The method of claim 3 , wherein the nasal daily dose is 0.1-10 mg mifepristone.7. The method of claim 3 , wherein the nasal daily dose is 0.5-5 mg mifepristone.8. The method of claim 3 , wherein the nasal daily dose is 0.75-2.5 mg mifepristone.9. The method of claim 2 , wherein mifepristone is formulated as a solution in an organic ...

Il-1 binding proteins

Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.

TOPICAL ANTISEPTIC SYSTEM

Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof. 137-. (canceled)38. A method of disinfecting tissue comprising: an iodophor comprising a carrier selected from the group consisting of a polyvinylpyrrolidone, a copolymer of N-vinyl lactam, a polyether glycol, a polyvinyl alcohol, a polyacrylamide, a polysaccharide, and combinations thereof; wherein the iodophor is present in an amount sufficient to provide an available iodine concentration of at least 0.25 wt-%;', 'a second antimicrobial agent;', 'a nonionic or anionic surfactant;', 'a thickening agent comprising a nonionic cellulose derivative or nonionic copolymer, or combination thereof; and', 'water;', said antiseptic composition is substantially free of any hydroxycarboxylic acid buffer; and', 'said antiseptic composition is substantially free of any fragrance; and, 'wherein], 'applying directly to tissue an antiseptic composition at use concentration, wherein the use concentration of the antiseptic. composition comprisesallowing the antiseptic composition to remain on the tissue; wherein the composition has a pH of 1.5 to 6.5.3941-. (canceled)42. A method according to wherein the nonionic copolymer comprises hydrophilic and hydrophobic regions.43. A method according to claim 42 , wherein the nonionic copolymer comprises a poloxamer.44. (canceled)45. A method of disinfecting skin of a subject comprising: prior to an invasive procedure claim 42 , [{'sub': '2', 'a first antimicrobial agent selected from the group consisting of I, an iodophor, and a combination thereof, wherein the antimicrobial agent is present in an amount sufficient ...

A NASAL SOLUTION WITH CLOSED BASIN NATURAL SPRING WATER CHARACTERISTIC AND METHOD FOR OBTAINING SAID NASAL SOLUTION

The present invention relates to a nasal solution used for elimination of nasal occlusions, for cleaning of the inner section of the nose and for the treatment of nasal diseases, wherein bicarbonate (HCO) is provided with weight proportion between 0.05% and 1.50% and carbonate (CO) is provided with weight proportion between 0.05% and 1.50% as the active substance in the ingredient thereof and it has alkali pH characteristic and preferably it is obtained from alkaline, closed basin natural spring waters. 1. A nasal solution for elimination of nasal occlusions and cleaning of the inner section of the nose and for the treatment of nasal diseases , the solution comprising:{'sub': '3', 'sup': '−', 'between 0.9% and 1.5% bicarbonate (HCO), and'}{'sub': '3', 'sup': '−2', 'between 0.9% and 1.5% carbonate (CO),'}wherein the solution is alkaline and hypertonic.2. The nasal solution according to claim 1 , comprising sodium (Na) claim 1 , chlorine (Cl) claim 1 , or both.3. The nasal solution according to claim 2 , comprising 0.1-1.60 wt. % sodium (Na).4. The nasal solution according to claim 2 , comprising 0.1-2.43 wt. % chlorine (Cl).5. The nasal solution according to claim 3 , wherein the mass proportion of bicarbonate (HCO)/sodium (Na) is between 0.4 and 1.9.6. The nasal solution according to claim 3 , wherein the mass proportion of carbonate (CO)/sodium (Na) is between 0.4 and 1.9.7. The nasal solution according to claim 1 , comprising:{'sup': '+', '0-0.1 wt. % potassium (K);'}{'sup': '+2', '0-0.1 wt. % magnesium (Mg);'}{'sub': '4', 'sup': '−2', '0-0.8 wt. % sulphate (SO); or'}any combination thereof.8. The nasal solution according to claim 1 , comprising{'sub': 3', '3, 'sup': −', '−2, '0.50 wt. % bicarbonate (HCO) and 0.80 wt. % carbonate (CO).'}9. The nasal solution according to claim 3 , comprising 0.80 wt. % sodium (Na).10. The nasal solution according to claim 4 , comprising 1.01 wt. % chlorine (Cl).11. The nasal solution according to claim 7 , comprising:{'sup': '−', ...

NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY

The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride.

METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS

The invention is a method and composition for treating a topical microbial infection in a subject. The method includes the step of administering a therapeutically effective amount of a polyether ionophore, or a therapeutically acceptable salt thereof, to the subject. 1. A method of treating a topical microbial infection in a subject , the method including the step of administering a therapeutically effective amount of a polyether ionophore , or a therapeutically acceptable salt thereof , to the subject , wherein the ionophore is applied topically.2. A method of preventing a topical microbial infection in a subject , the method including the step of administering a therapeutically effective amount of a polyether ionophore , or a therapeutically acceptable salt thereof , to the subject , wherein the ionophore is applied topically.3. The method according to or , wherein the administration is to the skin , nares , external ear canal or eye of the subject.4. The method according to any one of the preceding claims , wherein the polyether ionophore , or the therapeutically acceptable salt thereof , is selected from the group comprising monensin (also known as A-3823A) , narasin A (also known as A-28086A) , narasin B (also known as A-28086B) , narasin D (also known as A-28086D) , lasalocid , salinomycin , and maduramicin , semduramicin , tetronasin , alborixin (also known as S-14750A , CP-38 ,986) , laidlomycin (also known as AB-78) , lenoremycin (also known as A-130A , Ro21-6150) , A-130B , A-130C , dianemycin (also known as A-150 (M5-16183) , A-204A , A-204B , lonomycin (also known as A-218) , deoxylaidlomycin (also known as A-712) , calcimycin (also known as A-23187) , septamycin (also known as BL-580α and A-28695A) , A-28695B , K-41A (also known as A-32887) , BL-580β , BL-580δ , BL-580Z , carriomycin , calmycin(also known as A-23187) , cationomycin , chloronoboritomycin A (also known as X-14766A) , etheromycin (also known as CP-38 ,295 , C 20-12 , T-40517) , deoxy- ...

QUERCETIN-BASED COMPOSITION FOR TREATING RHINOSINUSITIS

The present invention concerns compositions for rinsing the nasal cavity and the sinus cavities for curative or prophylactic treatments of acute and/or chronic rhinitis, and acute and/or chronic sinusitis, comprising: 1. A composition for rinsing the nasal cavity and the sinus cavities for curative or prophylactic treatments of acute and/or chronic rhinitis , and acute and chronic sinusitis , comprising:sodium chloride and/or potassium chloride; quercetin, and at least one active agent of the polyphenolic group selected from the compounds: quercetin-4′-glycoside, 2-(3,4-dihydroxybenzoyl)-2,4,6-trihydroxy-3(2H)-benzofuranone, protocatechuic acid; andwherein the quercetin is in the anhydrous form with an approximate molecular mass of 302 g/mol, or in the form of quercetin hydrate with an approximate molecular mass of 320 g/mol, or in the form of quercetin dihydrate with an approximate molecular mass of 338 g/mol.2. The composition for use according to claim 1 , which further includes impurities derived from quercetin claim 1 , selected from: quercetin-3′-glycoside claim 1 , quercetin-7′-glycoside claim 1 , diglycosides and triglycosides of quercetin claim 1 , dimers of quercetin in an amount not exceeding 5% of the total amount of active agents.3. The dry composition for use according to claim 1 , comprising 94-99.99% by weight of sodium chloride and/or potassium chloride claim 1 , 0.000001-3% by weight of quercetin claim 1 , and 0.000001-3% by weight of 2-(3 claim 1 ,4-dihydroxybenzoyl)-2 claim 1 ,4 claim 1 ,6-trihydroxy-3(2H)-benzofuranone.4. The dry composition for use according to claim 1 , comprising 91-99.99% by weight of sodium chloride and/or potassium chloride claim 1 , 0.000001-3% by weight of quercetin claim 1 , 0.000001-3% by weight of 2-(3 claim 1 ,4-dihydroxybenzoyl)-2 claim 1 ,4 claim 1 ,6-trihydroxy-3(2H)-benzofuranone claim 1 , and 0.000001-3% by weight of quercetin-4′-glycoside.5. The dry composition for use according to claim 1 , comprising 91-99.77 ...

ORGANIC NASAL TREATMENT SOLUTION

A nasal spray or therapy solution is provided having organic glycerin; an organic preservative system containing glycerin, fruit extract, fruit extract, peel extract, ascorbic acid, citric acid, lactic acid, water; sodium chloride; water; whereby said nasal spray exhibits inhibited bacteriological growth in vitro for up to 36 months. 1. A nasal spray or therapy solution comprising:1-4% w/w organic glycerin;{'i': citrus reticulata', 'citrus aurantium amara', 'citrus aurantium sinensis, '0.5-4% w/w of an organic preservative system containing Glycerin, fruit extract, fruit extract, peel extract, ascorbic acid, citric acid, lactic acid, water;'}0.2-1.0% w/w sodium chloride; and91-98.3% Water; whereby said nasal spray exhibits inhibited bacteriological growth in vitro for up to 36 months.2. The nasal spray or therapy solution of comprising:1.5-2.5% w/w organic glycerin;{'i': citrus reticulata', 'citrus aurantium amara', 'citrus aurantium sinensis, '0.5-2% w/w of an organic preservative system containing Glycerin, fruit extract, fruit extract, peel extract, ascorbic acid, citric acid, lactic acid, water;'}0.4-0.7% w/w sodium chloride; and94.5-98% water; whereby said nasal spray exhibits inhibited bacteriological growth in vitro for up to 36 months.3. A nasal spray or therapy solution consisting of:2.0% w/w organic glycerin;{'i': citrus reticulata', 'citrus aurantium amara', 'citrus aurantium sinensis, '0.5% w/w of an organic preservative system containing Glycerin, fruit extract, fruit extract, peel extract, ascorbic acid, citric acid, lactic acid, water;'}0.65% w/w sodium chloride; and96.5% water; whereby said nasal spray exhibits inhibited bacteriological growth in vitro for up to 36 months.4citrus reticulatacitrus aurantium amaracitrus aurantium sinensis. The nasal spray or therapy solution of claim 1 , wherein said organic preservative system comprises a component ratio: fruit extract:fruit extract:peel extract:glycerine:ascorbic acid:citric acid:lactic acid:water of ...

Nasal dosage forms of dihydroergotamine

The present application relates to a nasal dosage form of dihydroergotamine, wherein said dosage form requires less than about 15 minutes for administration and requires less than four sprays to administer effective dose of dihydroergotamine for treating migraine in human subjects.

COMPOSITION AND METHODS TO IMPROVE STABILITY, DOSING, PHARMACODYNAMICS AND PRODUCT SHELF LIFE OF ENDOCANNABINOIDS, PHYTOCANNABINOIDS AND SYNTHETIC CANNABINOIDS DELIVERED BY NASAL INHAER

An inhaler-delivery-device-packaged homogenate of solid heterogeneous-lipid particulates carrying lipophilic cannabinoid receptor agonists and/or antagonists, wherein the solid heterogeneous-lipid particles comprises: one (or more) lipid(s) whose melting point(s) is (are) substantially above room temperature; in combination with, one (or more) lipid(s) whose melting point(s) is (are) substantially less than room temperature. 1. An inhaler-delivery-device-packaged homogenate of solid heterogeneous-lipid particulates carrying lipophilic cannabinoid receptor agonists and/or antagonists , said solid heterogeneous-lipid particles comprising:a. one (or more) lipid(s) whose melting point(s) is (are) substantially above room temperature; in combination with,b. one (or more) lipid(s) whose melting point(s) is (are) substantially less than room temperature.2. The inhaler-delivery-device-packaged homogenate according to claim 1 , comprising solid lipid particle of a homogenate selected from the group comprising:a. Solid lipid particle homogenate based on a compounded excipient comprised of a formulation of mutually compatible lipids including a first lipid having a melting point substantially greater than room temperature, and a second lipid having a melting point substantially below room temperature; or,b. Solid lipid particle homogenate of lipid phytoextracts fats/oils containing a first lipid having a melting point substantially greater than room temperature, and a second lipid having a melting point substantially below room temperature; or,c. A combination thereof.3. The inhaler-delivery-device-packaged homogenate according to wherein said first lipid comprises one or more saturated fatty acid(s) claim 2 , and said second lipid comprises one or more unsaturated fatty acid(s).4. The inhaler-delivery-device-packaged homogenate according to claim 3 , wherein said first lipid includes one or more of the group of unsaturated fatty acids comprising palmitic acid and stearic acid ...

Wax Foamable Vehicle and Pharmaceutical Compositions Thereof

Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided. 146-. (canceled)47. A foamble composition comprising a carrier and a liquefied hydrocarbon gas propellant , wherein the carrier comprises:a) a liquid wax comprising at least one fatty acid and/or at least one fatty alcohol;b) a stabilizer component comprising a non-ionic surface active agent and/or a polymeric agent; andc) water;wherein the ratio of the carrier to the gas propellant is about 100:3 by weight to about 100:35 by weight; andwherein, upon release from a pressurized container, the foamable composition produces a breakable foam.48. The foamable composition of claim 47 , wherein the fatty acid has 12-22 carbon atoms in its carbon backbone.49. The foamable composition of claim 47 , wherein the fatty alcohol has 12-22 carbon atoms in its carbon backbone.50. The foamable composition of claim 47 , wherein the fatty acid has 16-22 carbon atoms in its carbon backbone.51. The foamable composition of claim 47 , wherein the fatty alcohol has 16-22 carbon atoms in its carbon backbone.52. The foamable composition of claim 47 , wherein the fatty alcohol is a branched and/or unsaturated fatty alcohol.53. The foamable composition of claim 47 , wherein the fatty acid is a branched and/or unsaturated fatty acid.54. The foamable composition of claim 47 , wherein the liquid wax is present at a concentration of at least about 7.5% to about 60% by weight ...

Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

Compositions, devices and methods employing therapeutic concentrations of a triptan for treatment of migraine are described.

CARBOXYLIC ACIDS FOR TREATING/PREVENTING NASAL CONGESTION

The present invention relates to a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof as active ingredient for use in treating and/or alleviating and/or preventing nasal congestion, a viral infectious disease of the respiratory tract or an inflammation of the throat. Furthermore, the present invention relates to a method for treating and/or alleviating and/or preventing nasal congestion, viral infections of the respiratory tract and/or inflammation of the throat in. a patient, comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof. In addition, the present invention relates to a method for alleviating the symptoms associated with nasal congestion, viral infections of the respiratory tract and/or inflammation of the throat comprising administering an effective amount of a carboxylic acid or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof to a patient in need thereof. 114-. (canceled)15. A method for treating nasal congestion , viral infections of the respiratory tract , inflammation of the throat in a patient , or a combination thereof , the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a carboxylic acid or a pharmaceutically acceptable salt thereof.1618-. (canceled)19. The method of claim 15 , wherein the carboxylic acid or a pharmaceutically acceptable salt thereof comprises between two and four carbon atoms.20. The method of claim 15 , wherein the carboxylic acid or pharmaceutically acceptable salt thereof is one or more of acetic acid claim 15 , propionic acid claim 15 , butyric acid claim 15 , isobutyric acid claim 15 , 2-hydroxyproirinic acid ...

THE COMBINATION OF COTININE PLUS ANTIOXIDANT FOR TREATMENT-RESISTANT DEPRESSION AND CORRECTION OF ASTROCYTES FUNCTIONAL DEFICIT INDUCED BY DEPRESSION AND OTHER NEUROPATHOLOGICAL CONDITIONS

The present invention relates to a method of a) treating any of depression induced by chronic stress; depression in a subject afflicted with PTSD; anxiety induced by chronic stress; anxiety in a subject afflicted with PTSD; cognitive impairment induced by chronic stress; altered morphology and/or reduced number of GFAP+ cells in hippocampus and/or frontal cortex induced by chronic stress; working memory impairment in a subject afflicted with PTSD; b) inhibiting or reversing loss of GFAP+ cells in hippocampus and/or frontal cortex induced by chronic stress; c) decreasing consolidation of contextual fear memory in a subject afflicted with PTSD; d) enhancing extinction of fear memory in a subject afflicted with PTSD; or e) increasing calcineurin A expression in a subject afflicted with PTSD using a combination of cotinine and an antioxidant. 1) A method for treating depression induced by chronic stress in a subject comprising administering to the subject a therapeutically effective amount of cotinine or an isomer or racemate thereof , or a pharmaceutically acceptable salt thereof and an antioxidant , or a composition thereof , so as to decrease depression , thereby treating depression induced by chronic stress in the subject.2) A method for treating anxiety induced by chronic stress in a subject comprising administering to the subject a therapeutically effective amount of cotinine or an isomer or racemate thereof , or a pharmaceutically acceptable salt thereof and an antioxidant , or a composition thereof , so as to decrease anxiety , thereby treating anxiety induced by chronic stress in the subject.3) A method for treating cognitive impairment induced by chronic stress in a subject comprising administering to the subject a therapeutically effective amount of cotinine or an isomer or racemate thereof , or a pharmaceutically acceptable salt thereof and an antioxidant , or a composition thereof , so as to reverse cognitive impairment , thereby treating cognitive ...

METHODS AND COMPOSITIONS FOR REDUCING VANCOMYCIN-RESISTANT ENTEROCOCCI INFECTION OR COLONIZATION

The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria and/or the bacteria contribute substantially to resistance against vancomycin-resistant infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of 120-. (canceled)21Clostridium scindensBlautia productaClostridium scindensBlautia producta. A therapeutic composition comprising a Clostridiales VE202-05 bacteria and at least one of an isolated a bacteria , a bacteria , or both a bacteria and a bacteria.22Clostridium scindensBlautia producta. The composition of claim 21 , comprising both the bacteria and the bacteria.23. The composition of claim 21 , further comprising one or more additional species of bacteria selected from the group consisting of a member of the Bacteroidetes phylum and a member of the Firmicutes phylum.24. The composition of claim 23 , wherein the additional species of bacteria that is a member of the Firmicutes phylum is a member of the Lachnospiraceae family.25Barnesiella intestihominis, Blautia hansenii, Pseudoflavonifractor capillosus, Clostridium hiranonis, Clostridium hylemonae, Clostridium perfringens, Clostridium sordellii, Proteocatella sphenisci. The composition of claim 21 , further comprising one or more additional species of bacteria selected from the group consisting of a claim 21 , Lachnospiraceae 5_1_57FAA claim 21 , and Clostridiales VE202-26.26Clostridium scindensBlautia hansenii. The composition of claim 21 , comprising the bacteria and further comprising a bacteria.27Blautia productaClostridium bolteae. The composition of claim 21 , further comprising the bacteria and further comprising a bacteria.28Parabacteroides distasonis, Bacteroides sartorii, ...

LIPID NANOPARTICLE COMPOSITIONS AND METHODS AS CARRIERS OF CANNABINOIDS IN STANDARDIZED PRECISION-METERED DOSAGE FORMS

This disclosure teaches phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of cannabinoids, and create standardized precision-metered dosage forms of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid 2-fold to 8-fold, decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enable safe more efficacious cannabinoid therapy. 1. A nanosphere compositional structure comprising encapsulated cannabinoids dispersed into a stable adjustable fluid viscoelastic nanoparticle structure comprised of an outer single layer of essential phospholipids , liquid lipids and excipients; andwherein the nanoparticle structure has a particle size distribution from 50 to 150 nm.23.- (canceled)4. The nanosphere compositional structure of claim 1 , wherein the structure can be administered across the sublingual mucous mucosa and/or the buccal mucosa of a mammal and wherein the structure can enter the systemic circulation.5. The nanopshere compositional structure of claim 1 , wherein the structure is administered across dermal and/or the epidermal barriers and wherein the structure can enter the systemic circulation.6. The nanopshere compositional structure of claim 1 , wherein the structure can be administered across nasal mucous mucosal barriers and wherein the structure can enter the systemic circulation.7. The nanopshere compositional structure of claim 1 , wherein the structure can be administered across the intestinal mucosal barriers and wherein the structure can enter the systemic circulation.8. The nanosphere compositional structure of claim 1 , wherein the nanoparticle is ...

Gargle Method to Reduce the Duration of Common Cold Symptoms

A method of reducing the presence, duration, severity, or symptoms of the common cold entails the administration of a nonalcoholic antiviral remedy to a subject in need of such treatment, preferably in the form of a gargle. 1. A method of treating a patient to reduce the duration or symptoms of the common cold , comprising administering by a gargling method an aliquot of an herbal containing at least one agent selected from the group consisting of antivirals , astringents , acids , antibiotics , minerals , salts , and antimicrobials to a patient in need of such treatment.2. A method of treating a patient to reduce the duration or symptoms of the common cold , comprising administering by the oral route of administration an effective amount of a substance selected from the group consisting of hydrogen peroxide , baking soda , garlic , cayenne pepper , zinc , vinegar , citric acid , malic acid , oxalic acid , benzoic acid , quinic acid , tannic acid , ginger extract , olive whole leaf , fennel , eucalyptus or ascorbic acid effective to treat said patient.3. The method of claim 2 , wherein the nonalcoholic claim 2 , antiviral remedy comprises hydrogen peroxide.4. The method of claim 2 , wherein the nonalcoholic claim 2 , antiviral remedy comprises vinegar.5. The method of claim 2 , wherein the nonalcoholic claim 2 , antiviral remedy comprises ascorbic acid.6. The method of claim 2 , wherein the nonalcoholic claim 2 , antiviral remedy comprises food grade acids (citric claim 2 , malic claim 2 , oxalic claim 2 , benoic claim 2 , quinic claim 2 , tannic claim 2 , the unique combination of ingredients found in fresh ginger claim 2 , and any other food grade acid).7. The method of claim 1 , wherein the nonalcoholic claim 1 , antiviral remedy comprises citrus fruit (orange claim 1 , mandarin claim 1 , lemon claim 1 , lime claim 1 , etc.).8. The method of claim 2 , wherein the nonalcoholic claim 2 , antiviral remedy comprises honey.9. The method of claim 2 , wherein the ...

STABLE 5-METHYLTETRAHYDROFOLATE FORMULATIONS TO MODERATE METHYLENETETRAHYDROFOLATE REDUCTASE ASSOCIATED POLYMORPHISMS

Provided herein are methods for preparing stable solutions containing 5-methyltetrahydrofolate (MTHF). Also provided herein are stable compositions containing calcium 5-methyltetrahydrofolate (MTHF-Ca). 1. A method of preparing a solution containing 5-methyltetrahydrofolate retaining a potency of between about 90 to 110% for up to 40 days when stored under refrigeration , comprising the steps of:determining the weight of 5-methyltetrahydrofolate powder and sodium metabisulfite;determining the water content of the 5-methyltetrahydrofolate;adding an excess of between about 5% and 25% of 5-methyltetrahydrofolate powder;adding approximately 75% of the total desired volume of sterile water and mixing while keeping the mixture cold;mixing an appropriate amount of preservative into the mixture while keeping the mixture cold;adding a suitable gentle pH adjuster to adjust the pH to between approximately 3 and 9 while keeping the mixture cold; andadding enough sterile water to bring the mixture to the desired volume while protecting the mixture from light and keeping the mixture cold, wherein 5-methyltetrahydrofolate or a mixture containing 5-methyltetrahydrofolate is protected from light.2. The method of claim 1 , wherein the excess of 5-methyltetrahydrofolate powder is about 15%.3. The method of claim 1 , wherein the preservative comprises benzyl alcohol.4. The method of claim 1 , further comprising adding a suitable gentle pH adjuster to adjust the pH to between approximately 4 and 8.5. The method of claim 1 , further comprising adding a suitable gentle pH adjuster to adjust the pH to between approximately 5 and 5.7.6. The method of claim 1 , wherein the gentle pH adjuster comprises sodium phosphate dibasic solution between about 1%-20%.7. The method of claim 4 , wherein the gentle pH adjuster comprises sodium phosphate dibasic solution between about 1%-20%.8. The method of claim 5 , wherein the gentle pH adjuster comprises sodium phosphate dibasic solution between about 1 ...

METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT

The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal. 140-. (canceled)41. A liquid pharmaceutical composition formulated for administration through a nasal mucosal membrane comprising a therapeutic agent and an alkoxypolyethylene glycol represented by Formula I{'br': None, 'i': 'n', 'R—O—(CH2CH2O)-H\u2003\u2003(I),'}wherein R is methyl andn is a number in the range of from about 1 to about 25.42. The pharmaceutical composition of claim 41 , wherein the therapeutic agent is selected from the group consisting of hydrophobic therapeutic agents claim 41 , their pharmaceutically acceptable salts claim 41 , isomers claim 41 , esters claim 41 , ethers and other derivatives claim 41 , and mixtures thereof.43. The pharmaceutical composition of claim 41 , wherein the therapeutic agent is selected from the group consisting of an analgesic agent claim 41 , an anti-inflammatory agent claim 41 , an anti-arrhythmic agent claim 41 , an anti-asthma agent claim 41 , an anti-bacterial agent claim 41 , an anti-viral agent claim 41 , an anti-coagulant claim 41 , an anti-depressant claim 41 , an anti-diabetic claim 41 , an anti-epileptic claim 41 , an anti-fungal agent claim 41 , an anti-hypertensive agent claim 41 , an anti-malarial claim 41 , an anti-migraine agent claim 41 , an anti-muscarinic agent claim 41 , an anti-neoplastic agent claim 41 , an immunosuppressant claim 41 , an anti-protozoal agent claim 41 , an anti-thyroid agent claim 41 , an anxiolytic agent claim 41 , a sedative claim 41 , a hypnotic agent claim 41 , a neuroleptic agent claim 41 , a beta-Blocker claim 41 , a cardiac inotropic agent claim 41 , a ...

STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject. 1. An aqueous pharmaceutical composition for nasal administration to a human in the form of a single phase suspension comprising mometasone furoate and olopatadine hydrochloride , wherein the suspension remains in a single phase after 3 months of storage at 25±2° C. and 60%±5% relative humidity.2. The aqueous pharmaceutical composition of claim 1 , wherein the composition has a pH of between about 3.3 and about 4.1.3. The aqueous pharmaceutical composition of claim 1 , wherein the composition has an osmolality of about 200 mOsm/kg to about 400 mOsm/kg.4. The aqueous pharmaceutical composition of claim 1 , wherein the composition has an osmolality of about 250 mOsm/kg to about 350 mOsm/kg.5. The aqueous pharmaceutical composition of claim 1 , wherein the composition has a viscosity of about 20 to about 150 cps.6. An aqueous pharmaceutical composition for nasal administration to a human in the form of a single phase suspension comprising 25 μg mometasone furoate and 665 μg olopatadine hydrochloride claim 1 , wherein the suspension remains in a single phase after 3 months of storage at 25±2° C. and 60%±5% relative humidity.7. The aqueous pharmaceutical composition of claim 6 , wherein the pharmaceutical composition further comprising a hydrocolloid.8. The aqueous pharmaceutical composition of claim 7 , wherein the hydrocolloid comprises carboxymethylcellulose sodium.9. The aqueous pharmaceutical composition of claim 6 , wherein the pharmaceutical composition has a viscosity of about 20 cps to about 150 cps.10. The aqueous ...

STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject. 1. An aqueous pharmaceutical composition for nasal administration to a human in the form of a single phase suspension comprising mometasone furoate particles and olopatadine hydrochloride , wherein the mometasone furoate particles have a mean particle size of from about 1 μm to about 20 μm.2. The aqueous pharmaceutical composition of claim 1 , wherein the mean particle size of the mometasone furoate is from about 1 μm to about 15 μm.3. The aqueous pharmaceutical composition of claim 1 , wherein the composition has a pH of between about 3.3 and about 4.1.4. The aqueous pharmaceutical composition of claim 1 , wherein the composition has an osmolality of about 250 mOsm/kg to about 350 mOsm/kg.5. The aqueous pharmaceutical composition of claim 1 , wherein the composition has a viscosity of about 20 to about 150 cps.6. An aqueous pharmaceutical composition for nasal administration to a human in the form of a single phase suspension comprising 25 μg mometasone furoate and 665 μg olopatadine hydrochloride claim 1 , wherein the mometasone furoate particles have a mean particle size of from about 1 μm to about 20 μm.7. The aqueous pharmaceutical composition of claim 6 , wherein the mean particle size of the mometasone furoate is from about 1 μm to about 15 μm.8. The aqueous pharmaceutical composition of claim 6 , wherein the mometasone furoate is mometasone furoate monohydrate.9. The aqueous pharmaceutical composition of claim 6 , wherein the pharmaceutical composition further comprising a hydrocolloid.10. The aqueous pharmaceutical ...

STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject. 1. A sprayer containing an aqueous pharmaceutical composition in the form of a single phase suspension comprising mometasone or its salt and olopatadine or its salt , wherein the sprayer delivers a spray of the composition to a human nose that results in a spray pattern having a longest axis of 15-75 mm , a shortest axis of 10-65 mm , and an ellipticity of 1-2.2. The sprayer of claim 1 , wherein the suspension comprises mometasone furoate and olopatadine hydrochloride.3. The sprayer of claim 1 , wherein the pharmaceutical composition is a single phase suspension comprising 25 mcg mometasone furoate in particulate form and 665 mcg olopatadine hydrochloride in dissolved form.4. The sprayer of claim 3 , wherein the pharmaceutical composition further comprising a hydrocolloid.5. The sprayer of claim 4 , wherein the hydrocolloid comprises carboxymethylcellulose sodium.6. The sprayer of claim 3 , wherein the pharmaceutical composition has a viscosity of about 20 cps to about 150 cps.7. The sprayer of claim 4 , wherein the hydrocolloid is in an amount sufficient to inhibit phase separation for at least 24 hours when stored at 25±2° C. and 60%±5% relative humidity.8. The sprayer of claim 3 , wherein the mometasone furoate has a mean particle size in the range of about 1μm to about 20 μm.9. The sprayer of claim 3 , wherein the composition has a pH of about 3.3 to about 4.1.10. The sprayer of claim 3 , wherein the composition has a pH of about 3.5 to about 3.9.11. The sprayer of claim 3 , wherein the composition has an osmolality in the ...

STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject. 1. An aqueous pharmaceutical composition for nasal administration to a human in the form of a single phase suspension which comprises (a) mometasone or its salt in particulate form; (b) olopatadine or its salt in dissolved form , wherein the composition has a pH between about 3.3 to about 4.1.2. The aqueous pharmaceutical composition of claim 1 , wherein the pH of the composition is about 3.5 to about 3.9.3. The aqueous pharmaceutical composition of claim 1 , wherein the mean particle size of the mometasone furoate is from about 1 μm to about 15 μm.4. The aqueous pharmaceutical composition of claim 1 , wherein the composition has an osmolality of about 250 mOsm/kg to about 350 mOsm/kg.5. The aqueous pharmaceutical composition of claim 1 , wherein the composition has a viscosity of about 10 to about 150 cps.6. The aqueous pharmaceutical composition of claim 1 , wherein the composition remains in a single phase after at least 3 months of storage at 25±2° C. and 60%±5% relative humidity.7. An aqueous pharmaceutical composition for nasal administration to a human in the form of a single phase suspension comprising 25 μg mometasone furoate and 665 μg olopatadine hydrochloride claim 1 , wherein mometasone furoate is in particulate form; and olopatadine hydrochloride is in dissolved form wherein the composition has a pH between about 3.3 to about 4.1.8. The aqueous pharmaceutical composition of claim 7 , wherein the pH of the composition is about 3.5 to about 3.9.9. The aqueous pharmaceutical composition of claim 7 , wherein the ...

STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject. 2. A method of claim 1 , wherein the spray provides a droplet size distribution having a D10 of about 10-22μm claim 1 , D50 of about 35-45 μm claim 1 , and D90 of about 75-115 μm claim 1 , SPAN is not more than 3 claim 1 , and % Volume of <10 μm is not more than 5%.3. A method of claim 1 , wherein the composition comprises 25 μg mometasone furoate.4. A method of claim 1 , wherein the composition comprises 665 μg olopatadine hydrochloride.5. A method of claim 1 , wherein composition has a pH between about 3.3 to about 4.1.6. A method of claim 1 , wherein the pH of the composition is about 3.5 to about 3.9.7. A method of claim 1 , wherein the pH of the composition is about 3.5 to about 3.7.8. A method of claim 1 , wherein the mean particle size of the mometasone furoate is from about 1 μm to about 20 μm.9. A method of claim 1 , wherein the composition has an osmolality of about 250 mOsm/kg to about 350 mOsm/kg.10. A method of claim 1 , wherein the composition has a viscosity of about 10 to about 200 cps.11. A method of claim 1 , wherein the composition remains in a single phase after at least 3 months of storage at 25±2° C. and 60%±5% relative humidity.12. A method of claim 1 , wherein the composition results in a spray pattern having a longest axis of 15-75 mm claim 1 , a shortest axis of 10-65 mm claim 1 , and an ellipticity of 1-2.13. A method of claim 1 , wherein the composition further comprising a hydrocolloid.14. A method of claim 1 , wherein the hydrocolloid comprises carboxymethylcellulose sodium. This patent application ...

METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT

The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal. 140-. (canceled)42. The pharmaceutical composition of claim 41 , wherein the composition is formulated for administration to a rectal membrane.43. The pharmaceutical composition of claim 42 , wherein the therapeutic agent is selected from the group consisting of an analgesic agent claim 42 , an anti-inflammatory agent claim 42 , an anti-arrhythmic agent claim 42 , an anti-asthma agent claim 42 , an anti-bacterial agent claim 42 , an anti-viral agent claim 42 , an anti-coagulant claim 42 , an anti-depressant claim 42 , an anti-diabetic claim 42 , an anti-epileptic claim 42 , an anti-fungal agent claim 42 , an anti-hypertensive agent claim 42 , an anti-malarial claim 42 , an anti-migraine agent claim 42 , an anti-muscarinic agent claim 42 , an anti-neoplastic agent claim 42 , an immunosuppressant claim 42 , an anti-protozoal agent claim 42 , an anti-thyroid agent claim 42 , an anxiolytic agent claim 42 , a sedative claim 42 , a hypnotic agent claim 42 , a neuroleptic agent claim 42 , a beta-Blocker claim 42 , a cardiac inotropic agent claim 42 , a corticosteroid claim 42 , a diuretic agent claim 42 , an anti-Parkinsonian agent claim 42 , a gastrointestinal agent claim 42 , an anti-histamine claim 42 , a histamine-receptor antagonist claim 42 , a lipid regulating agent claim 42 , a muscle relaxant claim 42 , nitrate and other anti-anginal agent claim 42 , a nutritional agent claim 42 , an opioid analgesic claim 42 , sex hormone claim 42 , stimulant claim 42 , cytokine claim 42 , peptidomimetic claim 42 , peptide claim 42 , protein claim 42 , toxoid ...

BIFIDOBACTERIUM LONGUM ABLE TO BENEFICIALLY MODULATE IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION

An isolated strain of NCIMB 42020 is useful for the treatment of viral infections, especially viral respiratory infections such as influenza, rhinovirus and RSV. NCIMB 42020 is also useful for clearing secondary bacterial infections. 165-. (canceled)66Bifidobacterium longum. A formulation comprising a strain having the accession number NCIMB 42020.67Bifidobacterium longum. The formulation of claim 66 , wherein the strain is in the form of a biologically pure culture.68Bifidobacterium longum. The formulation of claim 66 , wherein the strain is in the form of viable cells claim 66 , non-viable cells claim 66 , or both viable cells and non-viable cells.69Bifidobacterium longum. The formulation of claim 66 , wherein the strain is in the form of a bacterial broth or a freeze-dried powder.70Bifidobacterium longumBifidobacterium longum. The formulation of claim 66 , further comprising a probiotic material other than the strain claim 66 , a prebiotic material claim 66 , or both a probiotic material other than the strain and a prebiotic material.71. The formulation of claim 66 , further comprising an ingestible carrier.72. The formulation of claim 71 , wherein the ingestible carrier is a pharmaceutically acceptable carrier chosen from a capsule claim 71 , a tablet claim 71 , or a powder.73. The formulation of claim 71 , wherein the ingestible carrier is a food product chosen from acidified milk claim 71 , yoghurt claim 71 , frozen yoghurt claim 71 , ice-cream claim 71 , milk powder claim 71 , milk concentrate claim 71 , ice cream claim 71 , cheese spread claim 71 , dressing claim 71 , or a beverage.74. The formulation of claim 66 , further comprising a protein claim 66 , a peptide claim 66 , or both a peptide and a protein.75. The formulation of claim 74 , wherein the protein claim 74 , the peptide claim 74 , or both the protein and the peptide is rich in glutamine/glutamate claim 74 , a lipid claim 74 , a carbohydrate claim 74 , a vitamin claim 74 , a mineral a trace ...

METHODS FOR IMPROVING THE COGNITIVE FUNCTIONS OF A SUBJECT

The disclosure provides for methods to improve the executive function of a subject by administering an effective amount of an oxytocin peptide, analog or mimetic. 1. A method of treating a subject that has an impairment in executive function or prophylactically preventing an impairment in executive function of a subject comprising , administering to the subject an effective amount of an oxytocin peptide or analog or a pharmaceutical composition comprising an effective amount of an oxytocin peptide or analog.2. The method of claim 1 , wherein the subject that has an impairment in executive function has a cognitive disorder selected from the group consisting of developmental disorder claim 1 , aphasia claim 1 , delirium claim 1 , dementia claim 1 , amnesia claim 1 , executive dysfunction and cerebrovascular disease.3. The method of claim 2 , wherein the developmental disorder is selected from the group consisting of attention-deficit hyperactivity disorder claim 2 , autism spectrum disorder claim 2 , and Asperger's disorder.4. The method of claim 2 , wherein the dementia is selected from the group consisting of Alzheimer's disease claim 2 , cortical dementia claim 2 , and subcortical dementia.5. The method of claim 1 , wherein the subject has an impairment in executive function has a mental disorder selected from the group consisting of Tourette's syndrome claim 1 , obsessive-compulsive disorder claim 1 , unipolar and bipolar affective disorder claim 1 , Schizotypal personality disorder claim 1 , corpus callosum dysgenesis claim 1 , impulsive personality disorder claim 1 , acute stress disorder claim 1 , and post-traumatic stress syndrome.6. The method of claim 1 , wherein the subject has an impairment in executive function has a disorder selected from the group consisting of Systemic Lupus Erythematosus claim 1 , Parkinson's disease claim 1 , rapid eye movement sleep behavior disorder claim 1 , and Huntington's disease.7. The method of claim 1 , wherein the subject ...

IONIC AQUEOUS COMPOSITIONS

Disclosed herein are ionic aqueous compositions useful as nasal passage washes to aid in the resorption of edema of the respiratory mucosa, e.g., the nasal mucosa, for the treatment of respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis, sinusitis, allergic rhinitis and nasal polyps. The composition includes an ionic aqueous solution and algae-derived constituents, such as branched, sulfated polysaccharides having an average molecular weight greater than 4 kDa and comprising L-fucose and sulfate ester groups or extracts from brown algae. Also disclosed are methods and pharmaceutical compositions for treating respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis. 1. A pharmaceutical composition comprising:an ionic aqueous solution; anda sulfated polysaccharide having an average molecular weight greater than 4 kDa and comprising L-fucose and sulfate ester groups.2. (canceled)3. The composition of claim 1 , wherein the sulfated polysaccharide is derived from an extract isolated from brown algae.4Undaria pinnafitida.. The composition of claim 3 , wherein the brown algae is5. The composition of claim 1 , wherein the sulfated polysaccharide is fucoidan.6. The composition of claim 1 , wherein the sulfated polysaccharide is in a range of about 0.1 to about 10% weight content of the composition.7. A pharmaceutical composition for nasal administration comprising:an ionic aqueous solution; andan extract from brown algae.8. The composition of claim 7 , wherein the brown algae extract is in a range of about 0.1 to about 10% weight content of the composition.9. The composition of further comprising an extract of a blue/green algae.10Spirulina platensis.. The composition of claim 9 , wherein the extract is isolated from11. The composition of claim 9 , wherein the extract is in a range of about 0.1 to about 10% weight content of the composition.1220-. (canceled)21. The ...

Nasal powder formulation for treatment of hypoglycemia

The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

COMPOSITIONS FOR DRUG ADMINISTRATION

The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. 1. An aqueous pharmaceutical composition comprising:a) an opioid compound; andb) an alkylsaccharide,wherein the composition has a pH of about 6.0 to 8.0.2. The composition of claim 1 , wherein the opioid compound is selected from the group consisting of hydromorphone claim 1 , oxycodone claim 1 , oxycontin claim 1 , roxicodone claim 1 , hydrocodone claim 1 , tramadol claim 1 , methadone claim 1 , tapentadol claim 1 , anileridine claim 1 , levorphanol claim 1 , buprenorphine claim 1 , heroin claim 1 , and fentanyl.3. The composition of claim 2 , wherein the opioid compound is hydromorphone.4. The composition of claim 1 , wherein the alkylsaccharide is undecyl maltoside claim 1 , dodecyl maltoside claim 1 , tetradecyl maltoside or sucrose dodecanoate.5. The composition of claim 1 , wherein the alkylsaccharide is undecyl-beta-D-maltoside claim 1 , dodecyl-beta-D-maltoside claim 1 , tridecyl-beta-D-maltoside or combination thereof.6. The composition of claim 5 , wherein the alkylsaccharide is dodecyl-beta-D-maltoside.7. The composition of claim 1 , wherein the concentration of alkylsaccharide is between about 0.01% and 20.0% by weight.8. The composition of claim 1 , wherein the concentration of alkylsaccharide is between about 0.05% and 10.0% by weight.9. The composition of claim 1 , wherein the concentration of alkylsaccharide is between about 0.05% and 5.0% by weight.10. The composition of claim 1 , wherein the concentration of alkylsaccharide is between about 0.05% and 2.0% by weight.11. The composition of claim 1 , further comprising ethylenediaminetetraacetic acid (EDTA).12. The composition of claim 11 , wherein the concentration of EDTA is about 0.01 claim ...

ACE2-Fc FUSION PROTEINS FOR SARS-COV-2 MITIGATION

The present disclosure relates to recombinant fusion proteins comprising an extracellular domain of the human angiotensin-converting enzyme 2 (ACE2), optionally having altered amino acid residues that result in increased binding affinity for the S1 spike protein of SARS-CoV-2, linked to a human immunoglobulin Fc region, that can extend the protein half-life (T1/2) and/or the duration of action as a decoy receptor, and compositions and methods of use of these fusion proteins.

Bismuth-Gadolinium Nanoparticles

Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided. 1. A composition , comprising:a nanoparticle core comprising one or more first linking groups covalently bonded to a first ligand and one or more second linking groups covalently bonded to a second ligand;{'sup': 3+', '3+, 'wherein one or more of the first ligands are complexed to Gd ions and one or more of the second ligands are complexed to Bi ions.'}2. The composition of claim 1 , wherein the nanoparticle core is a silica core.3. The composition of claim 1 , wherein the nanoparticle core is a polysiloxane core.4. The composition of any one of to claim 1 , wherein the one or more first linking groups each comprise a Calkylamine covalently bonded to the first ligand.5. The composition of any one of to claim 1 , wherein each of the first ligands is independently selected from the group consisting of 1 claim 1 ,4 claim 1 ,7-triazacyclononanetriacetic acid (NOTA) claim 1 , 1 claim 1 ,4 claim 1 ,7 claim 1 ,10-tetraazacyclododecane-1 claim 1 ,4 claim 1 ,7 claim 1 ,10-tetraacetic acid (DOTA) claim 1 , 1 claim 1 ,4 claim 1 ,7-triazacyclononane-1-glutaric acid-4 claim 1 ,7-diacetic acid (NODAGA) claim 1 , ethylene diamine tetra-acetic acid (EDTA) claim 1 , diethylene triaminepentaacetic acid (DTPA) claim 1 , cyclohexyl-1 claim 1 ,2-diaminetetraacetic acid (CDTA) claim 1 , ethyleneglycol-O claim 1 ,O′-bis(2-aminoethyl)-N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetraacetic acid (EGTA) claim 1 , N claim 1 ,N-bis(hydroxybenzyl)-ethylenediamine-N claim 1 ,N′-diacetic acid (MED) claim 1 , triethylene tetramine hexaacetic acid (TTHA) claim 1 , hydroxyethyidiamine triacetic acid (HEDTA) claim ...

Dissolving film for delivery of an active agent

A biodegradable film comprising a therapeutically effective amount of a Clostridial neurotoxin is described. Methods for treating rhinitis and for treating a symptom of rhinitis by administering the biodegradable film to the nasal cavity are also described.

COMPOSITION AND METHODS BASED ON NEUTRALIZING ANTIBODIES DELIVERED INTRANASALLY FOR ENHANCED THERAPEUTIC EFFICACY

The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies. 1. A composition formulated for intranasal or inhalation administration and effective for treatment or prophylaxis of influenza viral infection in a mammal comprising two or more influenza virus neutralizing monoclonal antibodies capable of neutralizing influenza A virus of at least two HA subtypes in a single unit dose of 1 mg/kg or less.2. The composition of comprising the influenza virus neutralizing monoclonal antibodies in a single unit dose of less than 0.5 mg/kg.3. The composition of comprising the influenza virus neutralizing monoclonal antibodies in a single unit dose of less than 0.1 mg/kg.4. The composition of comprising the influenza virus neutralizing monoclonal antibodies in a single unit dose of less than 0.05 mg/kg.5. The composition of wherein one or more of the influenza virus neutralizing monoclonal antibodies is an antibody fragment capable of influenza neutralization and selected from Fab claim 1 , Fab′ claim 1 , and F(ab′).6. The composition of further comprising a pharmaceutically acceptable excipient claim 1 , carrier or diluent claim 1 , an additive for nasal or pulmonary delivery claim 1 , or an immunological mediator or stimulator of the immune response.7. The composition of comprising a combination of influenza neutralizing antibodies comprising an antibody capable of neutralizing influenza A H1 virus claim 1 , an antibody capable of neutralizing influenza A H3 virus claim 1 ...

GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-α-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents. 1. A formulation comprising a zinc-α-glycoprotein (ZAG) , a ZAG variant , a modified ZAG , or a functional fragment thereof.2. The formulation of claim 1 , wherein the ZAG is mammalian.3. The formulation of claim 2 , wherein the ZAG is human.4. The formulation of claim 3 , wherein the ZAG consists of the amino acid sequence set forth in SEQ ID NO: 1.5. The formulation of claim 4 , wherein the ZAG is conjugated to a non-protein polymer.6. The formulation of claim 5 , wherein the ZAG is sialylated claim 5 , PEGylated or modified to increase solubility or stability.7. The formulation of claim 1 , wherein the ZAG is recombinant or synthetic.8. The formulation of claim 1 , wherein the modified ZAG consists of the wild-type ZAG amino acid sequence with one or more mutations to the amino acid sequence selected from deletions claim 1 , additions or conservative substitutions.9. The formulation of claim 5 , wherein the ZAG is glycosylated.10. The formulation of claim 1 , wherein the formulation comprises at least 5 claim 1 , 10 claim 1 , 25 claim 1 , 50 claim 1 , 100 mg of ZAG.11. The formulation of claim 1 , further comprising one or more agents selected from the group consisting of a β3 agonist and β-adrenergic receptor (β-AR) antagonist.12. The formulation of claim 11 , wherein the β-AR antagonist is selected from the group consisting of a β2-adrenergic receptor (β2-AR) antagonist claim 11 , a β1-adrenergic receptor (β1-AR) antagonist claim 11 , and a β3-adrenergic receptor (β3-AR) antagonist.13. The formulation of claim 11 , wherein the β3 agonist is selected from the group ...

Cyanocobalamin low viscosity aqueous formulations for intranasal delivery

A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

COMPOSITIONS AND METHODS FOR REGULATABLE ANTIBODY EXPRESSION

Compositions containing multiple different AAV stock are provided which allow for regulated expression of an immunoglobulin in a variety of tissues. Also provided is a method for regulating the dose of a pharmacologically active immunoglobulin. The method involves co-administering: (a) a first stock of recombinant AAV containing: an activation domain operably linked to expression control sequences comprising a promoter and a first nuclear localization signal; and a DNA binding domain comprising a zinc finger homeodomain and two or more FK506 binding protein domain (FKBP) subunit genes, wherein a first FKBP subunit gene and a second FKBP subunit gene have coding sequences which are no more than about 85% identical to each other, said DNA binding domain being operably linked to a second nuclear localization signal; and (b) a second stock of recombinant AAV comprising at least 2 to about 12 copies of a zinc finger homeodomain which are specific binding partners for the zinc finger homeodomain of the DNA binding domain, and further comprising at least one immunoglobulin expression cassette operably linked to inducible expression control sequences, such that when an effective amount of a rapamycin or rapalog is delivered transcription and expression of the immunoglobulin gene is induced. 1. An AAV composition for regulated expression of a recombinant immunoglobulin , said composition comprising: (i) an activation domain operably linked to expression control sequences comprising a promoter and a first nuclear localization signal; and', '(ii) a DNA binding domain comprising a zinc finger homeodomain and two or more FK506 binding protein domain (FKBP) subunit genes, wherein a first FKBP subunit gene and a second FKBP subunit gene have coding sequences which are no more than about 85% identical to each other, said DNA binding domain being operably linked to a second nuclear localization signal; and, '(a) a first stock of recombinant AAV in which the recombinant AAV contain a ...

COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE

Methods of treating a subject having heart failure including heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, and left ventricular hypertrophy-induced heart failure. The methods include activating hypothalamic oxytocin neurons in the brain of the subject and/or administering intranasally to the subject a therapeutically effective amount of oxytocin. Intranasal formulations for the treatment of a subject diagnosed with heart failure are also provided. 1. A method of treating a subject having heart failure with preserved ejection fraction , the method comprising activating cardiac vagal neurons (CVNs) in the brain of the subject by administering intranasally to the subject a therapeutically effective amount of oxytocin.2. The method according to claim 1 , wherein the therapeutically effective amount of oxytocin is from about 20 IU to about 100 IU.3. The method according to claim 2 , wherein the therapeutically effective amount is administered twice per day.4. The method according to claim 1 , wherein the therapeutically effective amount is from about 20 to about 40 IU b.i.d.5. The method according to claim 1 , wherein the subject does not have ischemic heart disease.6. The method according to claim 1 , further comprising administering to the subject a therapeutically effective amount of at least one of the group consisting of nitric oxide claim 1 , atrial natriuretic peptide (ANP) claim 1 , and beta-blockers.7. The method according to claim 1 , wherein the subject is a mammal or a human subject.8. A method of maintaining cardiovascular homeostasis and parasympathetic cardiac activity in a subject having heart failure with preserved ejection fraction claim 1 , the method comprising activating cardiac vagal neurons (CVNs) in the brain of the subject by administering intranasally to the subject a therapeutically effective amount of oxytocin.9. The method according to claim 8 , further comprising:causing at least one of the ...

ANTIMICROBIAL WASH

A method for detaching, removing or otherwise disrupting bacteria or biofilm by applying with pressure an antimicrobial wash. The antimicrobial wash contains a biguanide compound or mixtures thereof. 1. A method for removing biofilm comprising:applying with pressure an antimicrobial wash comprising a biguanide compound or mixtures thereof to a biofilm attached or adhered to a surface of a human or animal tissue, or on an implant device; anddetaching, removing or otherwise disrupting at least a part of the biofilm.2. The method according to wherein the pressure is about 30 claim 1 ,000 Pascal to 480 claim 1 ,000 Pascal.3. The method according to wherein the human or animal tissue is a nasal or sinus cavity.4. The method according to wherein the human or animal tissue is a middle or inner ear.5. The method according to wherein the biguanide is about 0.005 wt % to about 0.5 wt % of the total wash.6. The method according to wherein the biguanide is about 0.025 wt % to about 0.2 wt % of the total wash.7. The method according to wherein the biguanide is a polybiguanide.8. The method according to wherein the polybiguanide is a polyhexamethylenebiguanide or salts thereof and combinations thereof.9Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, Escherichia coli, Staphylococcus pneumonia, Haemophilus influenzaeMoraxella catarrhalis. The method according to wherein applying to the biofilm causes a greater than 1-log order reduction in a population of one or more or bacteria.10Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, Escherichia coli Staphylococcus pneumonia, Haemophilus influenzaeMoraxella catarrhalis. The method according to wherein applying to the biofilm causes greater than a 2-log order reduction in a population of one or more or bacteria.11Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, Escherichia coli Staphylococcus pneumonia, Haemophilus influenzaeMoraxella catarrhalis. The method ...

Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene

Methods and compositions for delivering medicine and other substances to the brain and the body via the cribriform plate using foamable compositions are described. Methods and compositions for improving nasal hygiene and moisturizing the nasal cavity using foamable compositions are also described.

THERAPEUTIC AGENT FOR RHINITIS

The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects. 1. A method of treating rhinitis in a subject in need thereof comprisingadministering to the subject a therapeutic preparation comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient,wherein CNP is selected from the group of consisting of CNP derivatives in which any amino acid in the amino acid sequence of CNP-22 or CNP-53 is deleted, substituted or added, and which has CNP activity,wherein the sequence of CNP-22 is SEQ ID NO: 1 and the sequence of CNP-53 is SEQ ID NO: 22,wherein BNP is selected from the group of consisting of BNP derivatives in which any amino acid in the amino acid sequence of BNP-26, BNP-32, or BNP-45 is deleted, substituted or added, and which has BNP activity, andwherein the sequence of BNP-32 is SEQ ID NO: 2, the sequence of BNP-26 is SEQ ID NO: 23 and the sequence of BNP-45 is SEQ ID NO: 24 or SEQ ID NO: 25.25.-. (canceled)6. The method of treating rhinitis according to claim 1 , wherein the C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) is a chimeric peptide of CNP and BNP forming a ring structure by an intermolecular disulfide bond claim 1 ,in which the CNP is a peptide selected from the group consisting of CNP-22, CNP-53, a peptide comprising any amino acid sequence of 5 or more consecutive amino acids in the amino acid sequence of CNP-22 having deletion(s), substitution(s), or addition(s) of any 1-5 amino acid(s), or a peptide comprising any amino acid sequence of 5 or more consecutive amino acids in the amino acid sequence of CNP-53 having deletion(s), substitution(s), or addition(s) of any 1-5 amino acid(s),and in which the BNP is a peptide ...